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ABSTRACT 
INTRODUCTION: The crCIHRt collaboration between Newfoundland and Ontario 
(2000-present) is an interdisciplinary study of the determinants of and impact from 
colorectal cancer (CRC) between these two Canadian provinces. It includes an evaluation 
ofthe adjuvant treatment ofCRC and overall survival from this common disease. Clinical 
Practice Guidelines (CPGs) for the adjuvant treatment of surgically curable (Stage I-III) 
colon cancer have not previously been evaluated in Canada. Canadian Cancer Statistics 
(CCS) have shown that overall survival from CRC is better in Ontario. The aims of this 
study were to evaluate whether adjuvant chemotherapy for Stage I-III colon cancer in the 
two provinces is concordant with accepted CPGs and to contrast overall survival from 
colon cancer in comparison with data from CCS. 
METHODS: In Newfoundland, all incident cases of colon cancer diagnosed between 
January 1, 1999 and December 31,2000, ages 20-74 were included. In Ontario, all patients 
with a high- or intermediate-risk pedigree and a random sample of those with a low-risk 
pedigree for colon cancer, ages 18-74, diagnosed between January 1, 1999 and June 30, 
2000 were offered participation in the study. Data was retrospectively retrieved using a 
standardized extraction form and quality assurance was undertaken through a random re-
extraction by two physician researchers. The charts of all patients with stage II disease 
were qualitatively assessed to determine what factors were used to recommend 
chemotherapy to these patients. This was contrasted with CPGs recommending 
chemotherapy only in stage II patients with 'high-risk' features. An overall survival 
comparison between the two provinces was contrasted with age-standardized projections 
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from CCS suggesting that Newfoundland experiences a worse overall survival than Ontario 
fromCRC. 
RESULTS: 173/274 (63%) and 364/514 (71 %) eligible patients consented m 
Newfoundland and Ontario, respectively. 
No one with stage I colon cancer in either province received adjuvant chemotherapy. 20/55 
patients (36%) in Newfoundland and 44/116 evaluable patients (38%) in Ontario received 
adjuvant therapy for stage II disease. 18/41 patients (44%) in Newfoundland and 30/53 
patients (57%) in Ontario with high-risk features received adjuvant treatment, significantly 
higher than patients without high-risk features. On multivariate analysis, age S 50 years 
was shown to be an independent predictor for the use of chemotherapy in stage II patients. 
45/52 patients (87%) in Newfoundland and 108/115 patients (94%) in Ontario with stage 
III disease received adjuvant chemotherapy. 
Kaplan-Meier survival analysis revealed that overall 5-year survival from colon cancer was 
significantly better in Ontario. Exclusion of patients consented by proxy in Newfoundland 
negated this survival advantage. 
DISCUSSION: Concordance with CPGs for adjuvant chemotherapy in stage II colon 
cancer was not optimal. This may reflect selection bias of referring surgeons, a paucity of 
level I evidence and the belief that other factors such as age may play a role in predicting 
outcome. Ontario showed a significantly better overall survival, however, this advantage 
was lost when bias introduced through recruitment methods was controlled for. Methods to 
ensure consistency and appropriate resource allocation in the development, adaptation and 
implementation of CPGs and the importance of minimizing bias in survival analysis are 
discussed. 
6 
INTRODUCTION 
Each year, there are approximately 17,000 patients diagnosed with colorectal cancer (CRC) 
in Canada.' In 2001 , there were 6400 deaths from this disease. CRC has the second 
highest cancer related mortality rate, and is the leading cause of death in the Western 
world. 2 Although screening has been shown to improve survival/·4•5 50% of patients in 
North America still present with either stage III or IV disease.6 Further, the total lifetime 
cost of treatment for colon cancer alone in Canada for the year 2000 was estimated at $333 
million.7 Most of this cost was comprised of hospital based investigations and treatment 
that resulted from the late discovery of the disease. These facts point to CRC as a major 
public health concern in Canada. 
In 2000, an interdisciplinary team of investigators from Newfoundland and Ontario were 
awarded a Canadian Institutes of Health Research (CIHR) grant for the collaborative study 
of the determinants of and impact from CRC. The overall objectives of the colorectal 
CIHR team (crCIHRt) were to evaluate and contrast molecular-genetic risk factors, risk 
modifiers and population health as they pertain to incident cases of CRC diagnosed in the 
two provinces. Broadly, the aims of the project were to discover novel genetic 
determinants of CRC by identifying new CRC-causing genes, identify genomic profiles 
based on common genetic variants that are predictive of CRC risk, explore whether there 
are inter-provincial differences in risk factors for CRC and in the presentation, treatment 
and outcome of CRC, develop and evaluate psychometric instruments for monitoring 
psychosocial and behavioral impacts of genetic testing, assess the efficacy of a risk and 
health counseling intervention among individuals who have a family history of CRC, 
evaluate whether patients pursue their risk-appropriate CRC screening, assess the impact 
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and explore the cost-effectiveness of CRC screening and polyp detection with regard to 
changes in HNPCC-related cancer risk, identify molecular-genetic markers that are 
associated with response to therapy and survival, detennine the contribution of genetic 
factors to CRC in older patients (age >75), and develop, evaluate and apply advanced 
statistical methods for the analysis of complex data relevant to CRC. The breadth of this 
project necessitated a multidisciplinary focus and included researchers from the fields of 
clinical epidemiology, statistics, internal medicine, genetics, pathology, nursing, surgical 
oncology and colorectal surgery amongst others. 
In most cases, CRC develops from adenomatous polyps.8 There is a continuum of change 
in the mucosa of the colon with progression from dysplasia to in-situ carcinoma and 
eventually invasive cancer. The progression is thought to take approximately 5 years, 
although the time course may be contracted in select cases such as those who are felt to 
clinically or genetically represent individuals from hereditary non-polyposis colorectal 
carcinoma (HNPCC) kind reds. 9 In order to improve overall survival rates, the disease 
needs to be detected at an early stage where intervention can impact favorably on long term 
outcome. Discovery of an abnormality early in the disease continuum, preferably at the 
stage of an adenomatous polyp or earlier, would be optimal. Population based screening 
tests aimed at the discovery of polyps have been evaluated and have been shown to 
decrease cancer rates and improve survival from CRC.3•4•5 However, once invasive 
malignancy has been diagnosed, survival rates can be improved only through the use of 
surgery and other effective adjuvant therapies. 
Strictly speaking, adjuvant therapy refers to the administration of a treatment following 
curative resection of all gross loco-regional disease. 10 In colon cancer (rectal cancer 
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excluded) adjuvant therapy could be considered for patients with loco-regional disease 
(Stage I-III) following curative resection of the primary tumor. Level I evidence from 
more than one randomized controlled trial supports the use of chemotherapy in stage III 
disease (node positive, no metastatic disease), but not in stage I disease (early cancer 
localized to the wall of the colon, node negative). 11 Adjuvant chemotherapy is 
controversial for stage II disease (tumor nearly or completely through the wall of the colon, 
node negative). As medical knowledge is vast and expanding rapidly, this type of 
information is often made available through the use of clinical practice guidelines (CPGs) 
formulated according to the tenets of evidence-based medicine. 
Evidence-based Medicine (EBM) 
The term 'evidence-based medicine' was coined in 1992 by a working group chaired by 
Gordon Guyatt at McMaster University. 12 It refers to the conscientious, explicit and 
judicious use of current best evidence in making decisions about the care of individual 
patients. It integrates aspects of the best research evidence, clinical expertise and patient 
values. New evidence replaces accepted practice with new diagnostic and therapeutic 
advances that are more powerful, acceptable and safer. It entails the identification of 
unique aspects of each clinical encounter, including potential individual risks and benefits, 
within a background of patient concerns and preferences. It emphasizes that intuition and 
unsystematic clinical experiences are not sufficient for well informed decision making. 
EBM encompasses two fundamental principles. 13 First, evidence alone is never sufficient 
to make a clinical decision. Risks, benefits, inconvenience, cost, alternate strategies and 
patient/physician values must always be taken into consideration and are extremely 
difficult to account for within the realm of EBM. Second, EBM provides a hierarchy of 
9 
evidence to aid in clinical decision making. Level I evidence, evidence obtained from the 
results of more than one well-designed, randomized controlled trial (RCT), provides the 
highest level of support. Less compelling evidence would be offered from the results of a 
single RCT (level II), followed by cohort studies (level Ill), case series (level IV) and 
expert opinion (level V) evidence. Any relationship, then, between two events could 
suggest potential 'evidence'. Physicians should be made aware of and attempt to apply the 
highest available evidence, preferably level I. However, evidence needs to be applied 
within the constraints of local beliefs, political environments and resource limitations. 
Level I evidence that people should be screened for a certain disease is not feasible if 
physicians do not believe in the test and resources would be lost from another area deemed 
to be more important. 
The need for the rapid dissemination of evidence-based medicine has arisen from our 
constant need for valid, reliable information regarding diagnosis, treatment, prevention and 
prognosis coupled with our inability to afford endless time per patient in the pursuit of 
tracking down and assimilating the best current evidence. The advent of resources 
committed to systematic review and valid concise summaries ( eg. the Cochrane 
Collaboration), the creation of evidence-based journals and the ability to access this 
information quickly from almost anywhere have aided in the ability of the clinical 
practitioner to effectively apply the tenets of lifelong learning to everyday practice. 
Advent of CPGs in Medicine 
Sackett has defined clinical practice guidelines as 'user-friendly statements that bring 
together the best external evidence and other knowledge necessary for decision-making 
about a specific health problem'. 14 They have three defining properties: they define 
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practice questions and explicitly identify all their decision options and outcomes, they 
explicitly identify, appraise and summarize, in ways most relevant to decision-makers, the 
best evidence about prevention, diagnosis, prognosis, therapy, harm and cost-effectiveness, 
and they explicitly identify the decision points at which the valid evidence needs to be 
integrated with individual clinical experience in deciding on a course of action. The 
clinician is not told what decision to make, but is given a range of potential decisions. 
Using the best evidence combined with clinical judgment and patients' values and 
expectations, the clinician will arrive at their own decision in the best interest of the 
individual patient. As such, the development and implementation of guidelines is a 
complex and fluid process, less concerned with the results of level I evidence and 
systematic reviews which are evidence-driven, but more concerned with the patient as they 
exist within their current social, economic and political context. Guidelines are 'necessity-
driven' 14 and tempered by current resources and social structure. Although they may 
incorporate aspects of systematic reviews, the best evidence may not be derived from well 
developed phase III randomized controlled trials with an appropriate control group. Thus, 
guidelines should provide information concerning highest levels of evidence for each 
recommendation set forth. 
The development, application and evaluation of clinical practice guidelines necessitate the 
practice of evidence-based medicine. A physician must ask three questions before adopting 
a specific clinical practice guideline into their practice. The physician must ask whether 
the guidelines are valid for the patient population served, whether the guideline is useful 
and whether the guideline can be applied in their own practice. 
Is a guideline valid? 
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The establishment of a valid guideline entails an exhaustive, non-biased review of the 
current literature. Each recommendation should be provided with a level of evidence and 
citation such that the original evidence upon which the recommendation is made can be 
readily accessed. Thus, the development is best carried out by a large collaboration of 
investigators encompassing a broad range of expertise in the area of interest. The 
investigators must be committed to the development of successive updates as new evidence 
becomes available. 
Is this guideline applicable to my patients within my practice or community? 
The applicability of a guideline will be determined mostly be local factors. The ability to 
determine whether a guideline is applicable within a certain community will rest on the 
strength of the recommendations. Good guidelines will clearly separate the evidence and 
what might be expected in the typical patient from recommendations as to how the 
guidelines should best be carried out. If a strong set of recommendations exist, then a 
number of questions must be answered before applying a particular guideline to a 
community or group of patients. 
1) Is there a significant burden of illness within the community? 
If the target illness (i.e. gastric adenocarcinoma) is infrequent, then the pre-test probability 
or expected event rate may be too low to warrant consideration of the guideline. 
2) Are the beliefs of patients or others in the community regarding the value of the 
intervention or consequences consistent with appropriate implementation of the guideline? 
If there is a belief that screening for colorectal cancer does not make a difference or that an 
intervention to prevent cancer is not a good use of resources (even in a high-risk 
community), then a guideline recommending intense population screening may not be 
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useful. 
3) Is the cost of implementing the guideline too high in terms of other community 
resources? 
A guideline that would decrease the waiting list time for surgery, but significantly increase 
the wait time for mental health assessment may not be acceptable. 
4) Are the barriers to implementation (i.e. geographic, organizational, legal, and 
behavioral) too large to overcome? 
If colonoscopy as a screening test for colorectal cancer would require the addition of 20 
experienced endoscopists doing nothing but colonoscopies, and there is no more endoscopy 
time currently available, the guideline would be difficult to implement without 
consideration of organizational issues. This is one of the most important considerations in 
the use of any guideline. 
Decision Analysis 
Decision analysis involves an integration of the hierarchy of best available evidence with 
values or preferences. It allows for elements of uncertainty, and it allows clinicians to 
compare and contrast the expected consequences of pursuing different strategies. As such, 
elements are open for debate and modification. 
These aids are often outlined graphically with the decision to be addressed on the far left, 
strategies in the centre and potential outcomes to the right. Extension of this type of 
analysis to issues of cost leads to an economic analysis that can aid in the interpretation of 
health care and resource utilization. 
Development of Quality CPGs 
Guideline Qualitv Appraisal 
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With the myriad of guidelines available for patient care, it is imperative that a means of 
applying scientific rigour to the guidelines themselves be available. In fact, once it has 
been determined that the need exists for a new, updated or modified set of CPGs, guideline 
developers should be aware of the end points that define quality before they set out to 
establish valid and useful guidelines. Health care providers and policy makers should 
know the quality of any set of guidelines before considering them for implementation in 
their practice environment. 
There have been many tools developed that seek to establish the quality of clinical practice 
guidelines. 15•16•17 The Guidelines International Network and the World Health 
Organization18 have endorsed the AGREE (Appraisal of Guidelines Research and 
Evaluation) instrument (www.agreecollaboration.org). 19,zo,zJ The instrument can be used by 
guideline developers, health care providers, policy makers and educators to ensure that the 
content of guidelines is valid and reliable. There are 23 elements in 6 domains (scope and 
purpose, stakeholder involvement, rigor of development, clarity and presentation, 
applicability and editorial independence) that can be assessed by at least 2 independent 
appraisers ( 4 recommended). An overall recommendation is then made as to whether the 
appraiser would recommend or not recommend the guidelines for use in everyday clinical 
practice. 
The AGREE instrument has been tested in 11 different countries in the first phase of its 
international project.20,21 Following modification; it was evaluated/validated in 18 
countries with reliable results. 
Adaptation and Implementation of CPGs: Knowledge Translation 
Adaptation 
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Adaptation of guidelines involves a systematic approach to the endorsement and/or 
modification of a guideline produced in a particular organization or cultural context for use 
in another.22 It is a process that can be used for customizing current guidelines rather than 
relying on the sequential development/publication of de novo guidelines for each region 
and/or locality (www.adapte.org).23 The rationale, well stated at the website, basically 
states that with limited time and resources and with the large input required for the 
development and maintenance of high quality guidelines, a means to adapt valid and well 
written guidelines to local circumstances is required. The aims of the ADAPTE 
consortium are to reduce the resources that go into the development of duplicate guidelines 
and perpetuate the use of well designed and validated guidelines that currently exist in 
many areas of medicine. The process involves a period of initiation to the aims of the 
process, a multidisciplinary review of current guidelines that exist for an important medical 
concern within the local community (given a prevalent condition, concern about current 
treatment and the overall perception that change is possible through guideline 
recommendations), acceptance in part or in whole of current guideline recommendations 
and development of an adapted guideline. Stakeholders are sought for input prior to 
implementation. It recognizes that guideline adaptation is part of a larger process that 
entails knowledge of the development of valid, high quality guidelines (ie. use of the 
AGREE instrument) and appropriate implementation strategies (see below). As such, it is 
part of the Guidelines International Network (GIN) that aims to ensure validity and 
reproducibility in all aspects of guideline use. The site includes a comprehensive manual 
and resource toolkit that can be obtained with minimal feedback to the ADAPTE 
investigators. 
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Dissemination and Implementation 
Dissemination has been defined as 'an educational intervention that aims at influencing 
targeted clinicians attitudes to, and awareness, knowledge and understanding of, a set of 
guidelines'. 24,25,26 Dissemination can be achieved through publications, postal distribution 
to the target audience, CME, professional development programs, symposia and lay/medial 
media.27 Publication alone fails. Implementation refers to 'turning changes in attitude and 
knowledge into changes in medical practice' or 'the concrete activities an interventions 
undertaken to turn policies into desired results' .28 
Most strategies have been directed at health care professionals rather than the patient, the 
medical department or health care organizations. Passive implementation strategies are of 
limited value. More recently, the concept of evidence-based implementation (EBI) 
strategies has arisen.29 These strategies involve the development of evidence-based 
guidelines based on a thorough description of evidence-practice gaps and barriers to change 
at the level of the patient, health care provider(s) and organization of the 
teams/departments. Guidelines should be simple and easy to use, based on reputable 
sources and simplify decision making. They should be based on good quality evidence, 
compatible with existing values and contain concrete descriptions of desired actions. As 
part of a whole process of implementation, reminders at both the group and individual level 
must be readily visible and audit/feedback of involved parties should be easily accessed. 
Impediments to the Implementation and Use of Guidelines 
It is well known that clinical practice guidelines have little effect on changing physician 
behavior.30•31•32•33 An exhaustive search of the literature has classified potential barriers 
into those involving physician factors (guideline awareness and familiarity, agreement with 
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guidelines, access to treatment/ability to overcome current practice inertia), patient factors 
(type of test, patient education) and issues surrounding resource allocation.33•34 It should be 
noted that this does not account for patient variables such as comfort with guidelines and 
belief in recommendations. 
Physician Barriers to the Implementation of Guidelines 
Physician awareness and familiarity 
The European Panel on the Appropriate Gastrointestinal Endoscopy (EPAGE) has 
evaluated the use of colonoscopy and conformity with guideline recommendations in 
Spain.35 350 sequential patients referred to an open endoscopy unit between May 1 and 
June 30, 2004 were assessed for an appropriate indication. 
Of350, 38 (11 %) were excluded as the indication given was not included in the guidelines. 
239/312 (77%) were deemed to have an appropriate indication and 73/312 (23%) an 
inappropriate indication. Diagnostic yield for those patients with an indication was 42% 
and without an indication was 21% (p=.OOl). There was a significant difference between 
specialties (gastroenterologists were more likely to suggest an appropriate indication) and 
as a result of patient age (older patients were more likely to have an appropriate indication). 
Although not directly evaluated in this study, the authors suggest that awareness and 
familiarity with guidelines was responsible for higher rates of appropriate indications in 
gastroenterologists. They suggest that the implementation of guidelines for the appropriate 
use of colonoscopy could improve suitable use of limited resources, decrease waiting times 
and facilitate access for appropriate indications. 
One study that specifically evaluated physician familiarity and implementation of 
guidelines for CRC screening involved interviewing 50 primary care physicians (1998-
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1999) in the Rehovot region of Central Israel and review of 1000 charts of their 
asymptomatic patients between the ages of 50 and 70.36 Rehovot is a densely populated 
area with easy access to medical care through a single centre. Screening guidelines had 
been widely disseminated and reviewed at several meeting targeting PCPs. 
Almost all participants endorsed screening. The appropriate use of FOBT and 
sigmoidoscopy was 40% and 12%, respectively. Only 4 (8%) were correct in the use of 
both techniques. Most estimated that >25% of the targeted population had been screened, 
when only 9211000 (9.2%) had FOBT and 14/1000 (1.4%) had sigmoidoscopy. There was 
no instance where a recommendation was made and subsequently declined by the patient. 
Only 2.6% of all CRC diagnoses were the result of screening programs. 
A second study explored the awareness of clinical practice guidelines for CRC screening in 
Canada.37 The authors wished to evaluate the effect of a revision in the Canadian Task 
Force on Preventive Health Care (CTF-PHC) guidelines on screening beliefs and clinical 
practice patterns of primary care physicians. A quasi-random sample of 160 physicians 
was undertaken in June-July 2001 and April-July 2002, the latter 9 months after publication 
of the guidelines. There was a 47% response rate. Recommendation of screening for 
average risk increased from 43% to 60% (p=0.02). 30% stated that the CTF-PHC 
guidelines were viewed as a source of information regarding CRC screening, and 24% 
were aware of revisions. Those who did not recommend average risk screening felt that the 
data were inconclusive and that the guidelines actually do not support screening. 
The authors acknowledge that there may be a multitude of factors responsible for the 
increased recommendation for screening and that the short time period from the publication 
to survey may not reflect the true impact of the guideline revisions. Similar to the 
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recommendation for chemotherapy for patients with high-risk stage II colon cancer, 
perceived inadequate strength of the data upon which guidelines were established may be 
responsible for low rates of adherence. 
These studies elegantly point to the downfall of viewing guideline development as devoid 
of the responsibility of ensuring a process by which implementation can be assessed. It is 
certainly not entirely the responsibility of the PCP to make themselves aware of all 
potential guidelines and to determine for which the practices of evidence-based medicine 
have been applied. The development, applicability, resource utilization and outcome 
assessment should be undertaken as an interconnected process that ensures improvements 
in overall patient health and care. 
Agreement with guideline recommendations 
Guidelines will need to be considered in the context of the local environment and may 
require modification and regular updates to reflect local circurnstances.38 In an Italian 
study exploring the use ofupper intestinal endoscopy for dyspeptic symptoms, endoscopy 
was recommended for patients under the age of 45.39 It was felt to be an appropriate 
recommendation for this locale as gastric cancer rates are high and found in a substantial 
number of people under the age of 45. The same degree of agreement may not hold in 
another environment where gastric cancer is less common in this age group and the return 
from endoscopic screening not deemed to be worthwhile. 
Access to treatment/ability to overcome practice inertia 
Concordance with guidelines has been shown to correlate with specialty interest and access 
to resources.40'41 A survey questionnaire of primary care physicians, internists, 
gastroenterologists and surgeons in Canada showed that specialists with ready access to 
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colonoscopy (gastroenterologists, surgeons) were more likely to recommend this test as a 
screening test to their patients. However, all respondents were equally as likely to agree 
that colonoscopy was the most sensitive and effective screen and the one that they would 
choose for themselves. 
Patient Barriers to the Implementation of Guidelines 
Type oftest 
There is some evidence in colorectal cancer screening that the type of test recommended 
can impact compliance rates.42 Using a cluster-randomized two-arm trial, these authors 
randomly assigned 20 general practitioners with an average of 150 patients between the 
ages of 50 and 74 to recommending either fecal occult blood testing (1449 patients) or 
sigmoidoscopy (1538 patients) as an initial screen. 
The probability of participation was statistically greater in patients randomized to invitation 
for FOBT (2.7, 95% CI = 2.0-3.8). I9.1% of the initial participants in the FOBT arm and 
I 0% in the sigmoidoscopy arm failed to complete testing. A statistically higher 
compliance rate was obtained with FOBT (17.2%, 95% CI = 2.5-25.7) than sigmoidoscopy 
(7.0%, 95% CI = 5.7-9.0). Multivariate analysis showed that the probability of testing 
decreased as the distance from the center increased (RR = 0.95 for I km increase, 95% CI 
= 0.9I-0.99) and that the type of provider impacted probability oftesting (RR = 0.60, 95% 
CI = 0.40-0.80). This again points to the influence of access and potential provider 
approach and/or bias on completion rates. 
Patient education 
In order to be appropriately counseled on guidelines and recommendations, members of the 
population must possess a certain level of education about a particular topic and have 
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access to appropriate resources. For example, the population must be made aware that 
even if they have no family history of CRC and no gastrointestinal symptoms (assuming 
they know the specific symptoms to look for}, diagnostic evaluations that may aid in the 
early detection of disease are available. 
The Precaution Adoption Process Model (P APM} suggests the steps that a person must 
proceed though prior to the adoption of a health-related behaviour.43•44 These include 1) 
unaware (no knowledge of a specific problem); 2) unengaged (knowledge, but not as to 
how it might apply to their specific circumstance); 3) deciding (aware that the problem may 
personally affect them, but undecided on what their reaction to this might be; 4) decision 
(yes or no); and, action. 
Thus, the first step in the education of the public is to make them aware that a specific 
problem exists. For example, may people believe that they need not worry about screening 
for colorectal cancer as they do not have any gastrointestinal symptoms. The public is not 
aware of a basic tenet of a screening test - that individuals be identified in a pre-
symptomatic phase at a point where a known and acceptable intervention will prolong life 
or prevent morbidity. This model further surmises that once the public is made aware of 
this fact, the individual still needs to recognize that this particular recommendation applies 
to them personally. A person might accept that screening is warranted in the asymptomatic 
phase, but feel that they lead a 'healthy' lifestyle and are therefore not at risk. It must be 
understood by the public that the current state of medical knowledge can only explain 
about 10-15% ofcolorectal cancer under the heading of 'genetic/familial'. 8 The remaining 
85-90% can not be explained definitively by any combination of exposure/environment 
factors. Thus, as a society we have chosen the age of 50 as the point at which average risk 
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individuals should begin screening for this disease. 
Presuming that we can target those over the age of 50, it is up to the individual to decide 
what their course of action might be. At this point in the process, it is imperative that the 
system have reasonable options available to the individual who presents for population 
based screening. There must be an easy and affordable avenue available for those who 
wish to take action. Unfortunately, neither Canada nor the United States is at a point where 
screening had progressed much beyond individual request/demand. Education and 
resource allocation have lagged behind recommendations/guidelines that have been put 
forth by subspecialty societies. 
Resource Barriers to the Implementation of Guidelines 
Resource allocation is not often overtly considered in the formulation and dissemination of 
clinical practice guidelines.45 The American College of Chest Physicians (ACCP) 
established a task force that met in March 2005 to consider how resource allocation should 
be incorporated into the development and structure of guidelines, including consideration 
of downstream differences in allocation. Omission ofresource related issues is not feasible 
in today's market. Policy makers and governments will unlikely be swayed unless strong 
consideration is given to cost, including alternative options where the resources might be 
more adequately distributed. 
The task force made several recommendations regarding incorporation of resource issues. 
Guideline developers should consider the inclusion of a health economist. This does not 
mean that each guideline needs an exhaustive delineation oftime and expense, rather that a 
structured approach be followed. A formal economic analysis might include consideration 
of health care alternatives and future cost savings in terms of the magnitude of cost 
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differential. 
Developers should also define the target audience. If the guidelines are felt to be widely 
applicable, then consideration should be given to a description of patient demographics and 
how these might be expected to impact on compliance. One component of this would be 
determination of the cost of an intervention per quality-adjusted life-year (QAL Y) gained. 
One model suggests that interventions in excess of 100 000 per QAL Y are unaffordable, 
while interventions costing < 20 000 per QAL Y are cost effective. 46 In a less affluent 
section of North America or in poor countries, 20 000 per QAL Y may not be feasible. 
Finally, developers need to consider how the target audience would be expected to respond 
to a particular recommendation. For example, two communities matched for socio-
economic status might be willing to 'pay' more or less for a particular health care benefit 
when competing forces are considered. 
Identification of Obstacles to Guideline Implementation 
Although tremendous efforts and resources have been expended in the development and 
implementation of clinical practice guidelines, there has not been great success noted in 
terms of documented improvements in health care. In fact, substantial waste of time, 
resources and manpower have been noted.47•48•49 It is important to note the factors intrinsic 
to the guideline that may result in failure, and to remedy these during development and 
early implementation. 
The implementability of a set of guidelines refers to the 'set of characteristics that predict 
the relative ease ofimplementation of guideline recommendations'.50•51 Toward this end, 
the Guideline Implementability Appraisal (GLIA) tool has been developed and validated to 
assist in the dissemination of clear, concise, valid guidelines. 51 
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The authors began by defining the attributes of a guideline that might be expected to impact 
on implementability. From this, 1 0 dimensions were developed consisting of 31 questions. 
The GLIA tool is available for download at http://ycmi.med.yale.edu/GLIA.52 The initial 
dimension (Global) contains 7 questions and refers to the instrument as a whole. Each of 
the remaining 9 dimensions (Decidability, Executability, Effect On Process Of Care, 
Presentation & Formatting, Measurable Outcomes, Apparent Validity, Novelty/Innovation, 
Flexibility and Computability) can be applied to each individual guideline 
recommendation. Each is given a rating of 'Yes - the recommendation meets this criterion 
fully', ' No - the recommendation does not meet this criterion', ' ? - rater is unable to 
address this question because of insufficient knowledge or expertise in this area', or 'NA -
criterion is not applicable to this recommendation'. Outside help should be obtained to 
resolve items marked by '?'. When 'No' is recorded, the barrier to implementation is 
recorded with a brief description. Suggested remedies are also noted. 
This tool was validated at the 2002 conference on Guideline Standardization. Good inter-
rater concordance was noted, with the observation that the criteria of executability 
(communicating exactly what to do) and decidability (communicating exactly when to 
carry out a response) seemed to be ultimately important. 
CPGs in Colorectal Cancer 
Although there have been numerous CPGs established for the screening, 53•54•55 
treatment 11 •56 and surveillance53•57•58 ofCRC, there have been limited resources dedicated to 
evaluation of the successful implementation of such. The translation of guidelines and 
other scientific evidence into clinical practice is extremely difficult. 59 It is estimated that 
up to 40% of patients do not receive care that might be compatible with highest level 
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scientific evidence; whereas 20% of patients may receive care that is otherwise harmful or 
not necessary. Even with well designed strategies, average changes of only about 10% in 
terms of guideline adherence have been reported. 30•31 •32 
CPGs: Adjuvant Treatment of Stage l-ID Colon Cancer 
The 1991 National Institutes of Health (NIH) Consensus Conference on the adjuvant 
treatment for colon and rectal cancer was the first recognized effort to establish guidelines 
for the standard postoperative treatment of this disease. 11 These guidelines have not been 
updated by the original authors, although subsequent reports have reinforced the 
conclusions and suggested a benefit to patients given adjuvant chemotherapy for 'high-risk' 
Stage II colon cancer.60•61 
NIH Consensus Conference Recommendation/ 1 
The treatment of co Ion cancer was considered separately from that of rectal cancer (defined 
as distal extent ofthe tumour within 12 em ofthe anal verge). Following review oflevel I 
evidence garnered from randomized controlled trials of adjuvant therapy for CRC, the 
authors of this paper concluded that there was adequate data to support a survival benefit 
from adjuvant 5-FU based chemotherapy administered following curative resection for 
Stage III (node positive) colon cancer. 
Adjuvant therapy (or stage II colon cancer- Systematic Review60' 61 
The National Surgical Adjuvant Breast and Bowel Project (NSABP) performed an analysis 
of the results of its four published trials on adjuvant chemotherapy: two comparing surgery 
alone with surgery plus adjuvant 5-FU based chemotherapy and two comparing different 
chemotherapy regirnes.60 1565/3820 patients (41 %) had stage II disease. Two pooled 
treatment groups were compared: one comprising the less effective treatment group from 
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each study and the second comprising the more effective group. There was a 30% relative 
reduction in risk in the more effective treatment group for the patients with stage II disease. 
Improvement in mortality was found for all subgroups studied, regardless of presence of 
adverse prognostic factors. However, the studies evaluated in this systematic review did 
not have the same treatment and control arms and there was no direct comparison of 
standard 5-FU/L V to surgery alone in any study. 
The International Multicentre Pooled Analysis of B2 Colon Cancer Trial (IMP ACT B2) 
analyzed the results from 5 RCT comparing 1016 patients with stage II disease randomized 
to 5-FU/LV (507) or observation (509).61 It did not find a survival benefit in the group that 
received chemotherapy. With a median follow-up of5.75 years, there was no difference in 
overall survival (82% vs 80%; HR = 0.86; 90% CI = 0.68-1.07) or event-free survival (76% 
vs 73%; HR = 0.83; 90% CI = 0.72-1.07). In the multivariate Cox analysis, age and 
tumour grade were the only independent predictors of overall and disease-free survival. 
Prognostic factors such as perforation, bowel obstruction, venous invasion and number of 
examined nodes were not included in this analysis. A subsequent pooled analysis of 7 
RCTs including those from IMPACT B2 showed an improvement in 5-year DFS in 1440 
stage II patients (76% vs 72%, p=0.05).62 However the difference in OS at 5 years was not 
significant (81% vs 80%, respectively). Significant histological predictors included tumour 
grade and bowel wall invasion. Other potential high-risk factors were not evaluated in this 
study. 
The consensus statement of the Fourth International Conference on Colorectal Cancer 
stated that 'the relative effect of chemotherapy is the same in Dukes' C (stage III) and in 
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Dukes' B (stage II) colon cancer; whereas the absolute survival benefit ts smaller m 
patients with Dukes' B cancer because their risk of death is smaller.63 
Subsequent to this declaration, the results from the QUASAR study have been published in 
abstract form. 64 Between June 1994 and December 2003, 3238 patients (91% with stage II 
disease) were randomized to either 5-FU based adjuvant chemotherapy or observation. At 
a median follow-up of 4.2 years, the 5-year survival rate was significantly better in those 
treated with adjuvant chemotherapy (80.3% vs 77.4%, HR = 0.83, 95% CI = 0.71-0.97) as 
was the 5-year disease-free recurrence rate (22.3% vs 26.2%, HR = 0.78, 95% CI = 0.67-
0.91 ). In evaluation of stage II patients only, there was a significant absolute reduction in 
the number of deaths with adjuvant chemotherapy, 224 vs. 262, p = 0.04. Final 
publication, including analysis of prognostic factors, is pending. 
It has been estimated that a randomized clinical trial of at least 4700 patients with stage II 
disease would be required in order to detect a 4% survival benefit at 5-years with an 
estimated baseline 5-year survival of 75%.65 There is no study that approaches these 
numbers, and it is unlikely that there even will be. 
CCO and ASCO recommendations for high-risk stage II colon cancei6•67 
Given the conflicting results of the systematic reviews, Cancer Care Ontario (CCO) and the 
American Society of Clinical Oncology (ASCO) have established expert panels that have 
performed their own meta-analyses.66•67 The results from both reviews have not shown a 
statistically significant benefit in terms of overall survival. However, certain patient and/or 
tumour characteristics in patients with stage II disease have been shown to be associated 
with a decrease in overall survival approximating survival of patients with stage III disease. 
For this reason, both CCO and ASCO have recommended that patients who possess these 
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'high-risk' characteristics be considered for administration of adjuvant 5-FU based 
chemotherapy. 
ceo guidelinei6 
This collaborative review assessed 37 RCTs and 11 meta-analyses (n = 20,317). In these 
studies the proportion of patients with stage II disease (either colon or rectal cancer) ranged 
from 23 to 100%. The evidence for stage II disease was derived mostly from the results of 
a meta-analysis including 1016 patients contrasting 5-FU/folinic acid vs observation alone. 
There was no improvement in disease-free or overall survival in patients who received 
adjuvant chemotherapy. 
Further meta-analysis was performed by the authors in 4187 patients ( 18 trials) that 
included a surgery alone arm. The reduction in relative risk of mortality was 0.87 (CI = 
0.75-1.01, p=0.07). However, adjuvant therapies were not consistent across included trials. 
The authors concluded that there is evidence to suggest improvements in disease-free 
survival with the use of adjuvant chemotherapy in patients with stage II disease, though not 
necessarily overall survival. They suggest that patients should be made aware of the 
evidence, and where appropriate offered participation in clinical trials. 
ASCO guidelinei7 
An expert panel was convened to address the issue of adjuvant chemotherapy for stage II 
colon cancer following curative resection as SEER-Medicare data suggested that a 
significant number of these patients were receiving chemotherapy without the benefit of 
conclusive data suggesting a benefit. The guidelines set forth sought to address whether all 
patients with stage II disease should be offered adjuvant therapy, whether identifiable high-
risk factors should guide chemotherapy and what factors clinicians felt were important in 
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offering adjuvant chemotherapy to patients with stage II disease following curative 
resection. The authors used data largely derived from the CCO consensus panel. 
Although systematic review did not support the routine use of adjuvant chemotherapy in 
stage II colon cancer following curative resection, the authors ofthe consensus panel stated 
that it should be considered in patients with 'poor prognostic factors' (clinical presentation 
with malignant bowel obstruction or perforation at the tumor site, poor differentiation, 
presence of lymphatic/vascular and/or perineural invasion and tumor aneuploidy). 
Subgroup analysis has shown that patients with these factors tend to have a survival in the 
range of patients with stage III disease. Therefore, it was recommended that adjuvant 
chemotherapy be considered. 
While molecular features such as tumor microsatellite instability (MSI) status may be 
important,68•69•70•71 these have not been emphasized in currently accepted guidelines. 
Although the approach to the treatment of stage II colon cancer is evolving, adjuvant 
treatment is currently recommended for high-risk stage II patients (clinical obstruction or 
tumor perforation at presentation, T4 lesion, poor differentiation, lymphatic invasion, 
perineural invasion, vascular invasion or mucin production)66•67 and all stage III patients 
following curative resection in an attempt to improve overall survival from this disease. 
Overall Survival: Stage I-III Colon Cancer 
Canadian Cancer Statistics (CCS) are developed by a Steering Committee ofthe National 
Cancer Institute of Canada (NCIC) and the Canadian Cancer Society (CCS).72-77 The 
Committee includes representatives of the NCIC, the CCS, Health Canada, Statistics 
Canada, the Canadian Council of Cancer Registries and university-
based/(provincial/territorial) cancer agency-based cancer researchers. The provincial and 
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territorial cancer registries are responsible for the review and supply of incidence data 
which form the basis of statistics published by the annual report. Statistics have been 
published every year since 1987. Information on the respective cancer registries can be 
accessed for Newfoundland & Labrador at www.nctr£n£ca78 and Ontario at 
79 
www .cancercare.on.ca. 
Data reported by CCS from 2002-2007,72-77 using actual reported deaths from CRC and 
estimated five-year age adjusted relative survival from CRC, showed that overall survival 
was better in Ontario as contrasted with Newfoundland (data for colon cancer alone not 
available). For example, estimated age-standardized mortality rates for CRC in 2002 were 
reported as 25/100,000 and 21/100,000 for males in Newfoundland and Ontario, 
respectively.72 The National estimate was 22/100,000 for this time period. The estimated 
age-standardized mortality rates for CRC for 2002 in women were reported as 14/100,000 
and 12/100,000 in Newfoundland and Ontario, respectively. The National estimate was 
14/100,000 for this same time period. This same trend was noted for each year between 
2002 and 2007.72-77 
The collaborative nature of the crCIHRt allows for a comparative evaluation of potential 
differences in overall survival between Newfoundland and Ontario for 1999 and 2000 
using a population-based approach. Further, this comparison can be contrasted with 
survival data reported by CCS that would suggest that survival from CRC in Newfoundland 
is worse than that reported in Ontario. 
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THESIS OBJEGTIVES AND AIMS 
The objectives ofthis thesis were to: 
1) Outline the NIH recommendations for adjuvant chemotherapy in colon cancer and the 
strength of evidence in support of adjuvant therapy for stage II disease. 
2) Determine concordance rates with clinical practice guidelines (CPGs) recommending 
adjuvant chemotherapy for high-risk stage II colon cancer patients in Newfoundland and 
Ontario. Paper accepted for publication in the Canadian Journal of Surgery. 
3) Explore factors involved in the development, adaptation and implementation ofCPGs. 
4) Outline sources of bias in the survival analysis for colon cancer in the crCIHRt study: 
Newfoundland vs. Ontario. 
5) Compare and contrast the objectives of and statistical approaches to survival analysis: 
crCIHRt vs. Canadian Cancer Statistics (CCS). 
The specific aims of this thesis were to: 
1) Evaluate whether the administration of adjuvant chemotherapy for Stage I-III colon 
(excluding rectal) cancer in the provinces ofNewfoundland and Ontario for the time period 
1999-2000 was concordant with accepted CPGs 
2) Compare and contrast overall survival from colon (not rectal) cancer in the crCIHRt study 
to data from CCS for the time period 1999-2000. 
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METHODS 
Study approvals 
All study procedures were approved by local IRBs and the advisory committee of the NIH 
Cooperative Family Registries for Colorectal Cancer Studies. 
Recruitment 
In Newfoundland, all incident cases of colon cancer in patients aged 20-74 diagnosed 
between January 1, 1999 and December 31 , 2000 were offered participation in the study. 
The Newfoundland & Labrador Familial Colorectal Cancer Registry (NFCCR) is a true 
population based registry that collected information on everyone diagnosed with CRC 
between the ages of20 and 74 years from 1999 to 2003. Each person with an ICD10 code 
to indicate colon (153) or rectal (154) cancer was identified by the Newfoundland Cancer 
Treatment and Research Center (NCTRC). Pathology reports were retrieved and reviewed 
by the team pathologist to ensure a diagnosis of adenocarcinoma, signet ring carcinoma or 
pseudomyxoma accompanied by adenocarcinoma. In this study, everyone diagnosed with 
colon cancer (153) had a letter forwarded to their attending physician as first contact 
describing the study as well as details of whom to contact should they be interested in 
participating. If an individual was deceased or at their preference, the next of kin was 
identified by several methods including family physicians, nursing clinics, etc. Each next 
of kin was then contacted in the same manner and asked to consent to a review of their 
affected family member' s medical records (proxy consent). This was undertaken as a 
means of improving recruitment into the study as data collection was initiated somewhat 
later in Newfoundland. 
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In Ontario, patients enrolled in the Ontario Familial Colorectal Cancer Registry (OFCCR), 
an NCI-funded consortium for the study of the genetic epidemiology of colorectal cancer, 
were asked to participate. The OFCCR is 1 of 6 international sites participating in the 
Cooperative Familial Registry for Colorectal Studies established by the NCI. The 
population-based Ontario Cancer Registry (OCR) was used to identifY all cases of invasive 
colon cancer diagnosed among residents of Ontario in patients aged 18-74 between January 
1, 1999 and June 30, 2000. Following completion of a family history questionnaire, all 
patients with a high- or intermediate-risk pedigree and a 25% random sample of patients 
with a low-risk pedigree were recruited into the study. Patients consented to the extraction 
of their medical records for information pertaining to the diagnosis and treatment of their 
disease. Proxy consents were not sought in Ontario. 
Chart extraction and data collection 
Following informed consent, medical records were retrospectively reviewed and abstracted 
by trained Health Record Technicians or Research Nurses. The standardized abstraction 
form (Appendix B) included information on patient demographics, diagnosis (symptoms, 
location of diagnosis, site of cancer and date of diagnosis), surgical intervention (date, type 
of surgery, operative findings, hospital/surgeon), pathology (stage, #lymph nodes, tumor 
differentiation/cell type, margins, perineuralllymphovascular invasion), adjuvant treatment 
(start date, type of chemotherapy), follow-up (metachronous primary, first documented 
locoregional and/or distant recurrence and treatment), time to last follow-up and/or death 
and cause of death. 
In order to verify the accuracy of data, approximately one half of the charts were randomly 
reviewed by two physician researchers. All records for patients with stage III disease who 
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did not receive adjuvant chemotherapy (n=14) were reviewed. The charts of patients with 
stage II disease were assessed to determine the presence/absence of high-risk features 
(clinical obstruction or tumor perforation at presentation, T4 lesion, poor differentiation, 
lymphatic invasion, perineural invasion, vascular invasion or mucin production) and 
whether these were used to guide chemotherapy recommendations. 
Statistical analysis 
Descriptive statistics were used where appropriate. i analysis was used to test for 
significant differences m categorical variables, including stage. Multivariate logistic 
regression was performed to identify independent predictors for receipt of chemotherapy in 
stage II patients. Kaplan-Meier survival analysis was used to contrast overall survival, in 
months, as a function of province of diagnosis. Cox Regression analysis was used to 
evaluate the proportionate variance attributable to defined factors in the assessment of 
overall survival. Results from the crCIHRt survival analysis were contrasted with 
information available for the same time period from CCS. 
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RESULTS 
Recruitment and Demographics 
In Newfoundland, there were 274 incident cases of colon cancer diagnosed between 
January 1, 1999 and December 31, 2000. 173/274 patients (63%) consented to participate 
in the study (Table 1). Of these, 117/173 patients (68%) were consented directly and 
56/173 (32%) were consented by proxy, either at the patient's request or because the 
patient was deceased. 
The Ontario Cancer Registry (OCR) recorded 2464 incident cases of colon cancer 
diagnosed in the province between January 1, 1999 and June 30, 2000. Of these, 1031 
(42%) completed a family history questionnaire and were recruited into the Ontario 
Familial Colorectal Cancer Registry (OFCCR). 979/1031 (95%) completed the 
questionnaire. All patients who were found to have a high-risk pedigree (28/979 patients, 
3%), an intermediate-risk pedigree (331/979 patients, 34%) and a 25% random sample 
(155/620 patients) of patients who reported a low-risk pedigree (155/979 patients, 16%) 
were deemed eligible for inclusion in this study (514/2464 incident cases = 21 %). 364/514 
(71 %) consented to participate. All 364 patients were consented directly as proxy consents 
were not sought in Ontario {Table 1 ). 
Demographic data for Newfoundland and Ontario can be seen by reference to Table 2. The 
proportion of subjects :S the age of 50 was approximately equal between the two provinces, 
whereas there were significantly more women in Newfoundland (i! = 7.34, p = 0.01, df = 
1). The overall stage at presentation was significantly more advanced in Newfoundland (i! 
= 33.200, p = 0.000, df= 3), with 25% ofpatients in Newfoundland and 9% of patients in 
Ontario being assigned stage IV status. When those consented by proxy in Newfoundland 
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were excluded from the data analysis, the significant effect of stage was lost ct :::: 6.154, p 
= 0.188, df :::: 4), with 7% of patients in Newfoundland now assigned stage IV status. This 
exclusion was performed as almost all patients consented by proxy were stage IV and the 
outcome of patients with stage IV disease consented by proxy was significantly different 
.from stage IV patients who were directly consented in Newfoundland (Figure 1). The 
median survival was approximately 9 months in 34 stage IV patients who were consented 
by proxy as contrasted with 25 months in 32 stage IV patients who were directly consented. 
Proxy consents were not sought in Ontario. 
There was no demographic data available for those patients who did not consent to 
participate in either province 
Adjuvant Chemotherapy as a function of stage 
Stage I - No adjuvant chemotherapy recommended by CPGs 
Of the 21 stage I patients in Newfoundland and the 60 stage I patients in Ontario, none 
were administered adjuvant chemotherapy (Table 3). 
Stage II- Chemotherapy recommended with high-risk features 
In Newfoundland, 20/55 stage II patients (36%) were initiated on adjuvant chemotherapy 
following curative resection (Table 3). 
Ofthe 55 patients diagnosed with stage II colon cancer in Newfoundland, 41 (75%) had at 
least one high-risk feature (Figure 2a). Of these high-risk patients, 29/41 (71 %) were 
referred to medical oncology and 18/29 patients (62%) were initiated on adjuvant 
chemotherapy (44% ofthe entire high-risk cohort). Therefore, 23/41 patients (56%) with 
high-risk features in Newfoundland were not offered adjuvant chemotherapy (Figure 3). 
12/23 patients (52%) were never referred to medical oncology by the operating surgeon or 
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family doctor. Of the 11 patients (48%) who were referred to medical oncology, one was 
felt to be medically unfit, one did not have the issue revisited after work-up for a benign 
liver lesion, 4 were noted to have 'high-risk features for which adjuvant chemotherapy has 
shown no definitive benefit', and 5 were felt to have 'no high-risk features' although at 
least one was noted in the standardized tumor pathology summary. 
14/55 stage II patients (25%) in Newfoundland were classified as low-risk (Figure 2a). Of 
these, 11/14 patients (73%) were assessed by medical oncology and 3/11 (27%) received 
adjuvant therapy (21% of the low-risk cohort). This was based solely on the presence of 
tumor ulceration. The latter was not strictly considered a high-risk feature for the purposes 
of this study as it is not identified in the CCO and ASCO guidelines. The receipt of 
adjuvant chemotherapy did not differ as a function of risk status in Newfoundland. 
In Ontario, 44/116 evaluable patients (38%) were initiated on adjuvant chemotherapy 
following curative resection (Table 3). The absence of standardized pathology reporting in 
the remaining 16/132 (12%) made this determination impossible. Most often, the presence 
oflymphovascular invasion was not noted. 
Of the 116 evaluable patients diagnosed with stage II colon cancer in Ontario, 53/116 
patients (46%) were high-risk and 63/116 patients (54%) were considered low-risk (Figure 
2b). Of 53/116 patients (46%) considered high-risk, 36 (68%) were referred to medical 
oncology and 17 (32%) were not. 30/36 patients (83%) referred received adjuvant 
chemotherapy. We were unable to determine from an assessment of the initial medical 
oncology consultations why the other 6 patients were not offered or initiated on adjuvant 
chemotherapy. 
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63/116 stage II patients (54%) in Ontario were classified as low-risk. Of these, 22/63 
patients (35%) were assessed by medical oncology and 14/22 (64%) received adjuvant 
chemotherapy (22% of the low-risk cohort). The reasons for this were not stated. The 
receipt of adjuvant chemotherapy differed significantly as a function of risk status in 
Ontario Ci = 14.0, p = 0.000, df= 1). 
Adjuvant chemotherapy as a function o(Age - Stage II 
As the proportion of low- and high-risk patients who received adjuvant chemotherapy 
(low-risk = 21% in Newfoundland and 22% in Ontario; high-risk = 44% in Newfoundland 
and 57% in Ontario) did not differ significantly as a function of province, data from the two 
provinces was combined for further analysis. 
Multivariate logistic regression was performed to identify independent predictors of those 
who received chemotherapy. Variables included in the model were High-risk status 
(relative odds = 3.82, 95% CI 1.87, 7.81), Province (NS) and Age > 50 at diagnosis 
(relative odds = 0.38, 95% CI 0.14-1.03). The proportion of those who received 
chemotherapy was 68% in those aged </= 50 years and 36% in those > 50 years. There 
was a strong trend towards using chemotherapy in the younger group independent ofhigh-
risk status. 
Stage III - Adjuvant chemotherapy recommended by CPGs 
The majority of patients with stage III colon cancer were administered adjuvant 
chemotherapy (Table 3). 
In Newfoundland, 45/52 (87%) patients with Stage III colon cancer received adjuvant 
chemotherapy. Of the 7 who did not, 3 patients died postoperatively, one had a delayed 
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postoperative course following an anastomotic leak, one was treated for a synchronous 
retroperitoneal lymphoma and three were not referred (no reason given). 
In Ontario, 108/115 (94%) were administered adjuvant chemotherapy. There was no 
information available for 4 patients, one patient refused therapy, one had metastatic breast 
cancer and there was no reason given for the final patient. 
Survival Analysis: crCffiRt- Ontario vs Newfoundland & Labrador 
Kaplan-Meier survival analysis comparing overall survival between Newfoundland and 
Ontario (Figure 4a) revealed that Ontario had a significantly better overall survival than 
Newfoundland (Mantel-Cox = 18.211, p = 0.000, df = 1). However, once the survival 
curves extend beyond approximately 12 months, they remain parallel for most of the 
duration ofthe comparison. Multivariate Cox Regression analysis, confirmed that most of 
the variation was noted in the first year after diagnosis (Figure 5). For this reason, patients 
consented by proxy were once again excluded from the analysis (Figure 4b). This resulted 
in a loss of significance in the statistical representation of the survival function (Mantel-
Cox = 3.073, p = 0.08, df = 1). The resultant Cox Regression analysis was now shown to 
cross unity for the first year following diagnosis (Figure 6). 
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DISCUSSION 
In 1991, the NIH published the first evidence-based guidelines for the use of adjuvant 
chemotherapy in colon cancer. 11 Level I evidence recommended adjuvant chemotherapy 
for stage III patients only. Although the findings from subsequent systematic reviews did 
not support the routine use of adjuvant chemotherapy in stage II patients, it should be 
considered in those with high-risk features. 66•67 
The results of our study revealed that patients with stage I and III colon cancer were 
managed according to current recommendations in both provinces. Clearly, guidelines 
supported by adequate level I evidence have been acknowledged by the appropriate target 
audience, including surgeons and medical oncologists, resulting in successful 
implementation. 
Although patients with high-risk stage II disease were significantly more likely to receive 
chemotherapy than patients with low-risk stage II disease, our data would suggest that 
other information was used in the decision to offer adjuvant chemotherapy to these 
patients. The Newfoundland data revealed that this was in part due to the failure of 
surgeons or family doctors to refer patients to medical oncology and in part due to the 
medical oncologists 'not believing in' or being unaware of the data with regard to high-risk 
stage II patients. We are unable to comment as to whether this reflects a lack of knowledge 
on the part of surgeons and/or family physicians as to the potential benefit for high-risk 
patients, whether surgeons and/or family physicians do not feel that the evidence is strong 
enough to warrant referral for stage II patients, or whether other factors such as resource 
allocation are at play. The failure of medical oncologists to recommend chemotherapy 
likely reflects a paucity of level I evidence or the belief that other factors are more 
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important in the decision to recommend adjuvant chemotherapy to this cohort of patients. 
Our data suggest that patient age influenced the decision to offer adjuvant chemotherapy in 
that age ,:S 50 was an independent predictor of chemotherapy use on multivariate analysis. 
This requires further investigation as younger age tends to be correlated with high 
frequency microsatellite instability (MSI-H) tumors.80•8 1 There is evidence that patients 
with MSI-H tumors may not derive the same benefit from 5-FU based chemotherapy.82 
Thus, the use of age alone as an adverse prognostic factor in the decision to administer 5-
FU based adjuvant chemotherapy may not be sound. The complex process of delineating 
which stage II patients should be considered for adjuvant chemotherapy following curative 
resection lacks the strong evidence base that has been well established in sound CPGs 
regarding adjuvant chemotherapy for stage III colon cancer patients. 
Mechanisms to Improve Concordance with CPGs for Stage II Colon Cancer 
Physicians are reluctant to change their behavior even in the face of evidence-based 
guidelines that seek to improve aspects of health care access, treatment and outcome. 83-87 
As previously discussed, the introduction of new guidelines does not automatically 
translate into doctor and/or patient acceptance.38 Further, improvements in compliance 
rates have been modest, in the range of 10%, for most implementation programs. Based on 
the known limitations to the effective implementation of guidelines as outlined in the 
preceding aspects of this paper, several authors have outlined a multidisciplinary approach 
to the development, dissemination and use of evidence-based guidelines. 
Scott et al (2004)88 have outlined a model that attempts to incorporate the interests and 
beliefs of all parties involved in order to establish a vested interest in guideline 
development and eventual incorporation into the clinical practice setting. In the case of 
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stage II colon cancer patients, this would refer to all physicians, other health care providers, 
administrators and others that have an interest in delivering the best available treatment 
within the constraints of resource allocation. Those invested in the process would start out 
by establishing a strict definition ofthe population to which the guidelines will refer, stage 
II colon cancer patients, acknowledging that the associated disease burden is a significant 
concern. Delineation of 'evidence-practice' gaps must be sought in order to strengthen the 
perceived need for guidelines to improve and standardize health care. A small number of 
interested individuals would then review the published literature with an aim toward 
acknowledgement of pre-existing valid guidelines and how these might be adapted with 
acknowledgment of the original source. Importantly, a panel of experts and potential end-
users, including local experts, would then convene to discuss the guidelines within the 
context oflocal conditions and beliefs. The two questions asked would be: 1) Who are the 
experts or senior clinicians who could criticize, disagree with, or disendorse the finished 
guidelines if not consulted during the development process? and 2) Who are the end-user 
clinicians who will ignore the guidelines if the latter fail to meet their clinical needs?. The 
aim of this panel would be to reach consensus based on strength of evidence and level of 
agreement, establish style of presentation, method(s) of dissemination and review/update 
schedules. 
Guideline structure should be as simple and unambiguous as possible. The use of the CCO 
and/or ASCO guidelines for the treatment of stage II colon cancer patients, in a format such 
as an easy to follow algorithm and/or flow charts should be used that incorporate clear and 
concise decision points. Access to further information should be easily referenced. 
Measures of risk and benefit should be reported where known and absolute risk reductions 
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should be made available when possible. Several small pilots of interested individuals 
should be employed prior to proposed widespread dissemination. 
While there are many systems available to implement guidelines, a multifaceted step-wise 
approach will lead to the greatest gains in compliance. Use of a system such as the 
PRECEDE model would be acceptable. 89 This model includes a predisposing phase, an 
enabling phase and a maintenance phase. 
The predisposing phase raises awareness of guidelines through discussions/presentations to 
targeted parties outlining evidence-practice gaps in the current care, such as when patients 
with stage II disease should be consulted to medical oncology. The easiest scenario might 
be to incorporate an algorithm that would have all patients with stage II disease referred to 
medical oncology following surgical resection of the primary colon tumour. Discussion 
would focus on the existing clinical culture and means by which patient care could better 
be achieved. The enabling phase allows users to better understand the full intent of the 
guidelines and how to access/apply them Guidelines would be readily accessible and 
educational strategies employed at regularly scheduled interactive, case-based small group 
seminars and workshops that allow for discussion of individualized application of the 
guidelines. This might include a discussion of when, how and if age should be considered 
in patients presenting for consideration of adjuvant therapy. Opinion leaders, involved in 
the prior development of the guidelines, should be readily used to promote uptake and 
detail likely improvements to be gained by the successful implementation ofthe guidelines. 
One-on-one support and electronic prompts, reminders and checklists should be available 
and incorporated into the patient care pathway. Support should be readily available. The 
maintenance phase consists of feedback of results and clinical audits. Anonymized peer-
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reference feedback on the group, specialty or hospital level should be provided. 
Use ofthis strategy has been shown, in at least one study, to significantly improve patient 
care over time.89 Significantly more patients received appropriate tests and medications 
during prescribed time limits when presenting with acute coronary syndrome (ACS). 
Baseline rates of several procedures (early coronary angiography) were already in the 90% 
range, and thus improvements were less noticeable. 
Although there are many more systems such as this described in the implementation 
literature,90•91 the basic principles of a multi-faceted approach with involvement of 
stakeholders from an early stage (guideline development), use of an 'awareness phase' , 
interactive educational strategies, access to support and ongoing audit, assessment and 
feedback are features of all. Guidelines need to be flexible and amenable to changes 
reflective of the local flavor. Only in this way can the main goals of guideline 
implementation - best application of evidence-based medicine, improved patient care 
(decreased morbidity, increased patient satisfaction and improved survival) and more 
effective. resource allocation - be realized. 
crCIHRt Kaplan-Meier survival analysis: Newfoundland vs. Ontario 
Kaplan-Meier survival analysis showed that Ontario enjoyed a significant overall survival 
advantage. At first glance, this seems reasonable given that it parallels data reported by 
CCS from 2002-2007,72-77 where actual reported deaths from CRC and estimated five-year 
age adjusted relative survival from CRC were better in Ontario (data for colon cancer alone 
not available). For example, estimated age-standardized mortality rates for CRC in 2002 
were reported as 251100,000 and 21 /100,000 for males in Newfoundland and Ontario, 
respectively. 72 The National estimate was 22/1 00,000 for this time period. The estimated 
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age-standardized mortality rates for CRC for 2002 in women were reported as 14/100,000 
and 12/100,000 in Newfoundland and Ontario, respectively. The National estimate was 
14/100,000 for this same time period. This same trend was noted for each year between 
2002 and 2007. However, it should be stated that while CCS estimates deaths from CRC 
for a particular year, the crCIHRt study retrospectively evaluated overall survival in a 
single cohort of subjects followed over time. 
The survival comparisons between Newfoundland and Ontario were not based on 
calculated age-standardized estimates of trends over time, but rather on evaluation of a 
defined cohort for the period 1999-2000. Survival analysis requires techniques that can 
deal with the censoring of data as not all subjects who will eventually ' experience the 
variable of interest' will have done so by the time that calculations are undertaken. 
Kaplan-Meier survival analysis is used to estimate the length of time to reach a certain 
endpoint, namely death. It is the conditional probability of surviva~ as defined by the 
hazard ratio, for each time interval given that a subject who has survived to the beginning 
of the interval will still be alive at the end. 92 The conditional probability of survival (the 
probability of surviving to the end of the interval given that the subject was alive at the 
beginning of the interval) is determined, with the product of the conditional probabilities 
defining survival to a particular point in time. These estimates of survival probabilities are 
represented, or modeled, as a survival curve. The curve represents a step function with 
sudden changes in estimated probability corresponding to the time that events occurred and 
indicated by vertical lines. The assumptions of Kaplan-Meier survival modeling are that: 
1) those patients who are censored will have the same survival as those who continue to be 
followed, 2) the survival probabilities are the same for subjects recruited early and late in 
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the study, and 3) that the event happens at the time specified. 
The three assumptions upon which the Kaplan-Meier survival analysis is based were not 
upheld in the crCIHRt survival comparisons. As such, bias introduced through differential 
methods ofl) recruitment of subjects (violation of assumption 2), 2) patient follow-up/time 
to data censor (violation of assumption 3), and 3) death recording (violation of assumption 
1) could account for most of the variance between the two provinces. The following 
discussion shows that control for these factors, when possible, can negate the significant 
survival advantage for colon cancer reported in Ontario by Kaplan-Meier survival 
modeling. 
Bias in recruitment methods - violation of the assumption that the survival probabilities 
are the same for subjects recruited early and late in the study 
The crCIHRt was established as a collaborative effort between the provinces of Ontario and 
Newfoundland in 2001. Recruitment of individuals to this arm of the study was initiated in 
Ontario approximately 2 years prior to initiation in Newfoundland. As such, 
Newfoundland investigators sought to recruit a similar ratio of subjects into the study by 
seeking 'proxy consent'. At the patient's request, or if the patient was deceased at the time 
contact was made, next-of-kin were approached to obtain consent for retrospective chart 
review. 32% of subjects recruited to the study in Newfoundland were obtained through 
proxy consent. In contrast, all individuals consented in Ontario were alive at the time of 
recruitment and were 'directly consented'. In order to explore the difference in survival 
between those consented by proxy and those directly consented, we looked specifically at 
the survival of stage IV patients in Newfoundland. Almost all patients consented by proxy 
were stage IV and had been consented for retrospective chart review after their death. The 
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median survival for stage IV patients consented by proxy in Newfoundland was 9 months 
in 34 patients as contrasted with stage IV patients consented directly in Newfoundland, 
where median survival was found to be 25 months in 32 patients. 
This inequity could account for the finding that the slopes of the Kaplan-Meier overall 
survival analysis become parallel after approximately 12 months and the suggestion from 
the Cox proportional hazards regression analysis that the major source of the variance is 
found within the first 12 months. For that reason, those consented by proxy in 
Newfoundland were excluded from the analysis. The subsequent survival statistic was not 
statistically significant and the Cox Regression model now crossed unity for the first year 
following diagnosis. This does not exclude other sources of bias in either direction or a 
true difference in survival between the two provinces. 
Bias in loss to follow-up/time of data censor- violation of the assumption that the event 
happens at the time specified 
In survival analysis, non-standardized protocols for follow-up can impact on statistical 
estimates. The Kaplan-Meier survival estimate is based on the premise that 'the probability 
of surviving k or more periods from entering the study is a product of the k observed 
survival rates for each defined period (the cumulative proportion surviving). 93 If survival is 
recorded in months, and follow-up is random or significantly different between two 
populations, then the measure of median survival will be skewed. The retrospective nature 
of the data procurement in the present study did not account for potential differential 
follow-up regimes in the two provinces. In fact, ASC094 recommends patients be followed 
' every 3 months for the first 2 years' while CC095 recommends that patients be followed 
'at least every 6 months for the first three years'. This is further confounded by the fact 
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that not all patient follow-up is performed by oncologists. Although we might expect these 
issues to have a more profound effect on recognition of recurrence, they might have also 
resulted in non-random effects on survival analysis given the fact that investigators in 
Newfoundland & Labrador relied on methods other than procurement of death certificates 
to ascertain survival data (see below under 'Bias in death recording'). Unfortunately, data 
related to follow-up patterns was not collected for this study, and thus, the impact or even 
the direction of such bias cannot be calculated or estimated. 
Bias in death recording - violation of assumption that those patients who are censored 
will have the same survival as those who continue to be followed 
In Ontario, survival data was obtained through the use of death certificates. OFCCR cases 
are linked with the Ontario Cancer Registry database. The latter is regularly updated with 
linkages through the Ontario Mortality database. In some cases, vital status information 
was received from relatives of deceased cases. Information on disease specific survival 
(DSS) was not available for analysis. In Newfoundland & Labrador, ethics approval did 
not allow for the use of death certificates. As such, investigators used clinic charts, 
obituaries from papers published across Newfoundland and family contact through the 
dedicated newsletter of the crCIHRt. Information was collected to allow for determination 
of disease specific survival (DSS). Data is not yet available as to how many subjects were 
lost to follow-up over the time course of the study. 
We cannot assume that both means of collecting survival data were equal in terms of 
delineating alive vs. dead. There is some data to suggest that there may be inaccuracy of 
up to 20% in death determination alone, depending on method of procurement, regardless 
of cause of death.96 These authors contrasted the accuracy of 4 methods of mortality 
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recording for 1999-2000 in a rural district of Vietnam. They looked at reported deaths in 
11,089 households collected by quarterly household follow-ups, census data, the Commune 
Population Registration System (CPRS) and a neighborhood survey. Using quarterly 
household follow-up as the gold standard, it was shown that the census missed 19 deaths, 
the CPRS missed 89 deaths (19%) and the neighborhood survey over-reported actual 
deaths. The fact that overall survival was significantly worse in Newfoundland may be 
partly explained by factors associated with the different means of death ascertainment in 
the two provinces. As with method of follow-up, the presence and/or direction ofthis bias 
cannot be ascertained given the retrospective nature of this study. 
As disease specific survival (DSS) was not directly assessed m Ontario, no direct 
comparison between the provinces was possible in the crCIHRt study. However, it has 
been shown that death certificates can be extremely inaccurate.97-100 A meta-analyses 
showed that at least 1/3 of death certificates are likely to be incorrect, mostly the result of 
inaccurate recording of cause of death.98 Many of these errors likely arise as the result of 
limited previous experience with the patient prior to their death, house staff inexperience, 
fatigue, time constraints and perceived unimportance of the death certificate.97•101 The 
means of ascertaining death and cause of death in Newfoundland may have allowed the 
investigators access to more complete, or at the least different, information. This would 
have made comparisons ofDSS, if possible, fraught with potential bias. 
crCIHRt vs Canadian Cancer Statistics 
The following discussion contrasting the survival analyses for colon cancer in the crCIHRt 
study and mortality information derived from CCS for CRC is hypothetical given that the 
central purpose and statistical methods invoked differ between the two reports. In fact, 
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CCS explicitly acknowledges that "It is not appropriate to compare the age-standardized 
rates presented here with those from publications that employ a different standard 
population".72-77 Therefore, the main purpose of this section is to contrast statistical 
methods used in the derivation of incidence and mortality data as they relate to the central 
purpose of the data. 
Central purpose: crCIHRt vs Canadian Cancer Statistics 
crCIHRt 
The crCIHRt was initiated in 2001 as a joint effort by a multidisciplinary team of 
investigators from Newfoundland and Ontario to study incident cases of CRC in the two 
Canadian provinces. The collaboration was established through the CIHR when funding 
was sought to fulfill similar aims by investigators in the two provinces. The objective was 
to compare and contrast epidemiologic, genetic and nutritional influences on the incidence 
and mortality related to colorectal cancer between the two provinces for a single, defined 
period oftime. Use of a population-based study was an important element that resulted in 
an accurate assessment ofthe most important variable currently related to cancer outcome, 
stage of disease. As such, the study sought to delineate important environmental and 
genetic influences on the development of CRC cancer and to explore resource allocation 
and outcome, as a function of stage, between the two provinces. Although it sought to act 
as the impetus for further research, it was not meant to aid, explicitly, in decision making, 
priority setting or resource allocation at the individua~ community or provincial level. 
Canadian Cancer Statistics 
The main purpose of CCS is to provide health professionals, investigators and policy-
makers with information pertaining to the incidence and mortality of common cancer types 
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by age, gender, time period and province/territory.72-77 It acts, through the use of 
standardized statistical estimates, to stimulate new research and assist in decision-making 
and priority setting at all levels. As such, the data provided deals not only with time point 
estimates of incidence and mortality, but with actual and estimated trends over time. 
Statistical methods: crCIHRt vs Canadian Cancer Statistics 
crCmRt 
Colon cancer i11cidence or survival rates were not calculated as part of the crCIHRt study 
as this was not necessary to fulfill the central objectives of the study. However, it was 
possible to make crude comparisons between Newfoundland and CCS, as the actual 
number of reported cases of CRC for 1999 and 2000 were recorded in the Newfoundland 
arm of the study and can be compared to those extracted for the corresponding years from 
the 2003 73 and 2004 74 Canadian Cancer Statistics, respectively. For the two years 
combined, there were 420 reported cases in males and 270 reported cases in females for a 
total of 690 cases reported to CCS by the Newfoundland Cancer Registry. If we assume 
that 70% were colon cancer based on previous estimates, 102 there should be about 483 
patients diagnosed with colon cancer in Newfoundland between January 1, 1999 and 
December 31 , 2000. As our study was limited to patients between 20 and 74, we would 
have excluded some of these people. It is likely, however, that some patients were missed 
by our study as over 200 patients are unaccounted for and not all of these would be 
expected to fall outside the defined age range. The reasons for this are uncertain as the data 
was extracted from the same source. 
In the crCIHRt study, overall mortality was evaluated usmg Kaplan-Meier survival 
analysis. The main outcome measure was estimated time to death for a cohort of patients 
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from Newfoundland or Ontario diagnosed with colon cancer from 1999 to 2000. 
Canadian Cancer Statistics 
The statistical analysis employed by CCS involves the standardization of incidence and 
mortality rates based on the 1991 Canadian population in order to provide appropriate age-
standardized rates. 72-77 Data provided by the provincial and territorial cancer agencies is 
used in conjunction with projected changes in population size and distribution (ie. age, 
gender) supplied by Statistics Canada to estimate the probability of developing and dying 
from cancer, as well as potential years of life lost to this disease. Incidence and mortality 
rates are estimated for each age group, cancer site and gender by fitting Poisson regression 
analyses to the provincial and territorial yearly values. Poisson regression assumes that 
annual incidence fulfills the criteria of independent Poisson random variables with a mean 
which is the product of the annual population size and the (true) annual incidence rate.72-77 
It further assumes that the length ofthe observation period is fixed in advance and that the 
events occur at a constant average rate. It is used to model random events in time and 
expresses the probability of a number of events occurring in a fixed period of time if these 
events occur with a known average rate and independently of the time since the last event. 
The Poisson distribution is a nonparametric statistic used to estimate rates when the 
outcome measure is rare in the overall population. It can be used to estimate future rates 
based on past performance and projected future census data. The purpose is not to define 
the survival function for a particular cohort of patients, but rather to estimate burden of 
future disease to aid in planning and resource allocation. Estimates from CCS have 
performed well in comparison to actual data which becomes available, on average, with a 
delay of 4-5 years.34-39 Unlike the crCIHRt, assumptions of the Poisson distribution, 
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including a fixed observation period and events occurring at a constant average rate over 
time, are met by annual reporting of provinciaVterritorial incidence and mortality data and 
the use of projected estimates based on pasts trends or averages over time. Follow-up is 
not an issue as data modeling of future mortality rates is not cohort dependent, but based 
rather on past incidence trends and projected population size. 
Outcome measures: crCIHRt vs. Canadian Cancer Statistics 
The central question that we wished to address by comparison to CCS was whether 
crCIHRt data was accurate and whether there truly exists a greater incidence and mortality 
from CRC in Newfoundland as suggested by data in actual and projected estimates ofCCS. 
It would appear that our data is not complete and that there are sources of statistically 
immeasurable bias that do not allow us to answer this question. 
The finding of different projected survival estimates using the data accrued from the 
crCIHRt (Kaplan-Meier Survival Estimate, Newfoundland vs. Ontario) and CCS (Age-
standardized Poisson regression estimates of incidence and survival by province) reflects 
differences in stated objectives and statistical analyses based on the type of data collected. 
In fact, direct comparison of the conclusions from the two sources is not valid given that 
data was collected to fulfill different purposes. The crCIHRt sought to compare two 
provinces at a point in time in order to determine if differences existed between the two 
populations in terms of stage at presentation, treatment and outcome. It was meant to 
answer questions related to how well things have been done in the past. In contrast, CCS 
sought to project incidence and mortality data based on past trends and estimated 
population size. It was meant to answer questions related to how resource and manpower 
allocation should proceed into the future. Thus, estimates of a higher incidence and 
53 
mortality burden in Newfoundland vs. Ontario as reported by CCS are reliable and 
reproducible given the Poisson method. 
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CONCLUSIONS 
1) The strength of evidence in support of chemotherapy for high-risk stage II colon 
cancer patients is level 5 (Expert recommendations based on the best available data 
from multiple systematic reviews). 
2) The concordance rates in Newfoundland and Ontario with CPGs recommending 
adjuvant chemotherapy for high-risk stage II colon cancer patients were low. It 
appeared that other factors, including age, were considered. 
3) The development, adaptation and implementation of CPGs is a complex process 
that should incorporate validated tools that address each of these aspects. 
4) The assumptions of Kaplan-Meier survival analysis were violated in the comparison 
of overall survival between Newfoundland and Ontario. Only the contribution of 
time of entry into the study could be statistically controlled for through the 
exclusion of those consented by proxy in Newfoundland. 
5) As the objectives of and statistical approaches to survival analysis differed between 
the crCIHRt and CSS, direct comparisons of survival are not valid. 
The rise of evidence-based medicine has lead to the development of clinical practice 
guidelines that are aimed at providing and standardizing the best medical care for the 
population within the confines of resource limitations. The use of guidelines is a complex 
process that demands expertise in the areas of literature assessment and guideline 
development, adaptation to a particular population and set of circumstances and 
implementation strategies. Those interested in guideline development need to consider the 
appropriate questions to ask, what the best available data would recommend and 
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mechanisms of dissemination, adaptation and implementation. There are numerous 
methods that have been developed and standardized by multidisciplinary expert panels that 
address the issues surrounding each of these areas. It is imperative that those involved with 
guideline development be aware of these tools and use them in order to develop valid, 
reproducible guidelines that can be reasonably implemented at the level of the target 
audience given local circumstances and potential resource limitations. As this is a resource 
intense process, both in terms of financial resources and manpower, validated instruments 
that have been developed to assist in all aspects of this process should be considered. 
International collaborative efforts at all levels will hopefully lead to more standardized 
patient care, within the limits of local resource limitations and beliefs. Only in this way 
can improvements in patient care including decreased morbidity, increased patient 
satisfaction and improvements in overall and disease specific survival be accurately and 
reproducibly recognized. 
Accurate determination of survival is an equally complex process. The methods used by 
the crCIHRt investigators violated all assumptions of the Kaplan-Meier survival statistic. 
Bias introduced through differential methods of subject recruitment, ill-defmed patient 
follow-up protocols and dissimilar means of assessment of the outcome of interest needs to 
be minimized. Comparisons of this nature that extend over more than one locality need to 
be highly controlled, starting at the point of what research questions are valid and 
reasonable given available data. Unfortunately, aside from bias introduced secondary to 
method of recruitment into the study, we are unable to statistically control for other factors. 
All statistics used in survival analysis, such as the log-rank test and Cox proportional 
hazards regression analysis, make similar assumptions and thus may not be valid to analyze 
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this data. Therefore, unless it can be confirmed that similar times to follow-up were used 
in each province and death certificates are made available for comparison in 
Newfoundland, the conclusions of our data are not statistically sound. 
Database development, such as that described for the study of CRC by the crCIHRt, needs 
to become more standardized and reproducible across time and place. As has been shown, 
unless comparable entry times and follow-up protocols are in place, the resultant bias will 
make it difficult to draw valid conclusions from comparative studies of this nature. 
Prospective collaborative databases that attempt to capture accurate, reproducible data will 
be best suited to answer the types of questions addressed in this paper. Only in this way 
will valid results that can guide future treatment protocols and legitimate guidelines be 
realized. 
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Newfoundland Ontario 
Total eligible 274 514 
Total Consented 173 (63o/o) 364 (71 °/o) 
Direct Consent 117 (68o/o) 364 (1 00°/o) 
Proxy Consent 56 (32°/o) 0 
Table 1. Method of consent: Newfoundland vs. Ontario 
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Newfoundland Ontario 
Number Consented 173 364 
Age~50 20 (12o/o) 56 (15o/o) 
Age> 50 153 (88o/o) 308 (85°/o) 
Female 73 (42°/o) 183 (50o/o) 
Male 100 (58°/o) 180 (50o/o) 
Stage I = 21 (12°/o) I= 61 (17°/o) 
(Proxies included) II = 57 (33°/o) II= 141 (39°/o) 
III = 52 (30°/o) III = 115 (31 o/o) 
IV= 43 (25o/o) IV= 31 (9°/o) 
Unknown 16 (4°/o) 
Stage I= 20 (17°/o) 
(Proxies excluded) II= 50 (43°/o) See 'Proxies included ' 
III= 39 (33°/o) 
IV= 8 (7°/o) 
Table 2. Demographics of Study Population 
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Newfoundland Ontario Total 
Stage at Diagnosis 
Stage I 0/21 0/60 0/81 
Stage II 20/55 (36%,) 44/116 (38 o/o) 64/171 (37°/o) 
Stage III 45/52 (87o/o) 108/115 (94o/o) 153/167 (92°/o) 
Table 3. Adjuvant Chemotherapy by Stage 
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KaplarrMeier sur\1val estimates, by proxy 
1.00 
0.75 
0.50 
0.25 
0.00 yes 
0 20 40 60 
analysis time 
Figure 1. Kaplan-Meier Survival Analysis, Newfoundland: direct (no) vs. proxy 
(yes) consent 
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55 stage II patients 
I 
I I 
41/55 (75°/o) high-risk 14/55 (25o/o) low-risk 
29/41 (71 °/o) 11/14 (73°/o) 
referred to med one referred to med one 
18/29 (62°/o) 3/11 (27o/o) 
offered chemotherapy offered chemotherapy 
Figure 2a. Receipt of adjuvant chemotherapy as a function of risk status in Newfoundland (Stage II) 
116 stage II patients 
I 
I I 
53/116 ( 46°/o) high-risk 63/116 (54°/o) low-risk 
36/53 (68°/o) 22/63 (35°/o) 
referred to med one referred to med one 
30/36 (83o/o) 14/22 (64°/o) 
offered chemotherapy offered chemotherapy 
Figure 2b. Receipt of adjuvant chemotherapy as a function of risk status in Ontario (Stage II) 
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Figure 3. Fate of stage II patients who were high-risk who did not receive adjuvant 
chemotherapy 
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Figure 4a. Kaplan-Meier Survival Analysis, Overall Survival Newfoundland 
vs. Ontario 
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Figure 4b. Kaplan-Meier Survival Analysis, Overall Survival Newfoundland 
vs. Ontario (proxies excluded) 
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Cox model of patient survival 
stratified by chemotherapy 
~ed@dg1(1.03; 1.00, 1.05) 
N... vcr.J, 0->1 yr(8.39; 2.8, 25) 
N... vcr.J, 1->2 yr(1.12; 0.54, 2.32) 
N... v (J\J, 2->4 yr (1.1; 0.64, 1.86) 
314v1/2,0->1 yr(28.6; 5.5, 147) 
314 v 1/2, 1->2 yr(6.5; 1.9, 22.6) 
314 v 1/2, 2->4 yr(3.93; 1.7, 8.9) 
-
1.00 3.16 
Hazard R:ltio (log scale) 
• 
-
10.00 
• 
31 .62 100.00 
Figure 5. Cox Proportionate Regression Analysis, Survival Newfoundland vs. 
Ontario 
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Aged @ dgn (1 .03; 1 .00, 1.07) 
Cox model of patient survival 
stratified by chemotherapy 
NL vON, 0->1 yr (2.86; 0.72, 11 .2) 
NL vON, 1->2 yr (0.15; 0.02, 1.2) 
NL vON, 2->4 yr (0.63; 0.32, 1.25) 
3/4 v 1/2, 0->1 yr (68.5; 6.85, 685) 
3/4 v 1/2, 1->2 yr (2.72; 0.71' 10.3) 
3/4 v 1/2, 2->4 yr (4.19; 1.8, 19.73) 
-
0.03 0.10 0.32 1.00 3.16 10.00 31 .62 316.23 
Hazard Ratio (log scale) 
Figure 6. Cox Proportionate Regression Analysis, Survival Newfoundland vs. 
Ontario (proxy consents excluded) 
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APPENDIX A-DATA EXTRACTION FORM 
8 1 
Name: ____________________________ _J ____________________________ __ 
LAST FIRST 
Sex: 
0 Male 
0 Female 
0 Unknown 
Date of Birth: 
I~ I 
CLINICAL DIAGNOSIS AND TREATMENT- BASELINE 
1. Place of Diagnosis: I Name I City or Town I MOH Code 
2. Site of Cancers : 
Cancer Site Name 4-Di it ICD-9 Code 
1. 
2. 
3. 
4 . 
5. 
3. Date of initial diagnosis of colorectal cancer (please use histological date i.e. Date of pathology 
report): 
DD 
MM 
yyyy 
0 Unknown 
4. Preoperative symptoms (please check all that apply): 
0 None, asymptomatic (detected by screening) 
0 Bleeding 
0 Constipation 
0 Diarrhea 
0 Pain 
0 Weight Loss 
0 Other Please Specify: 
0 Unknown 
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5 Mthd f ctl e 0 o co ore a cancer d" lag nOS IS: 
0 Colonoscopy 
0 Rigid sigmoidoscopy 
0 Flexible sigmoidoscopy 
0 Sigmoidoscopy NOS 
0 Barium enema 
0 Chest x-ray 
0 Chest CT scan 
0 Abdominal/Pelvic CT scan 
0 Ultrasound 
0 Other Please Specify: 
0 Unknown 
.. 6. Type of defin1t1ve surgery for colorectal cancer (SEER codmg used) (please attach all pathology and 
operative reports for this colorectal cancer): 
0 None 
0 Local tumour destruction, i.e. laser, electrocautery 
0 Local surgical exdsion with specimen i.e. polypectomy, snare 
0 Segmental resection, not hemi-colectomy i.e. cecectomy, appendectomy, sigmoidectomy, partial 
resection of transverse colon and flexures, iliocolectomy, enterocolectomy, partial colectomy, NOS 
o Low Anterior 
0 Hemi-colectomy, but not total. Right or left, must include a portion of transverse colon 
0 Abdomi no peri neal resection 
0 Total or subtotal colectomy, not rectum 
0 Colectomy NOS 
0 Segmental colectomy+ other organs (*Please specify below) 
0 Hemi-colectomy + other organs (*Please specify below) 
0 Total or subtotal colectomy or + other organs (*Please specify below) 
0 Abdominoperineal resection+ other organs (*Please specify below) 
0 Other Please Specify: 
0 Unknown 
0 
0 art of colon resection 
0 
0 Pancreas 
0 Small intestine 
0 Liver 
0 Abdominal Wall, Retroperitoneum 
0 Adrenal 
0 Kidne 
0 Bladder 
0 Urethra 
0 Ova 
0 Uterus 
0 Va ina 
0 Prostate 
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I ~ I Other Please Specify: Unknown 
7 If rf d no surgery was pe orme reason: 
0 Patient Refusal 
0 Antecedent Death 
0 Medical Contraindication 
0 Other Please Specify: 
0 Unknown 
8 s IS f d. ease from pathology report only: ummary o 
pT 
pN 
pM 
0 Unknown 
10 P th I · I Stage of disease (from all information available): a orogrca 
T 
N 
M 
0 Unknown 
11 s f d" tage o rsease at initial diagnosis (from all information available) 
0 
0 
0 
0 
0 
0 
Yes 
0 
Stage 0 
Stage 1 
Stage 2 
Stage 3 
Stage 4 
Unknown 
Identified: 
o Crohn's Disease 
0 Ulcerative colitis 
o Diverticulosis/it is 
o Perforation 
o Other Please S eci 
13. Preoperative CEA (carcinoembryonic anti~ en): 
0 Yes ug/L 
0 No 
0 Unknown 
14. Date of Blood Test for Preoperative CEA: 
~~~ I I 
No Unknown 
0 0 
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I~ I 
15 D t f a e o surgery: 
DD 
MM 
yyyy 
D Unknown 
16. Primary surgery hospital: I Name I City or Town I MOH Code 
17. Operating Surgeon: 
18. Operative findings, local (residual tumour) (please obtain information from the operative report 
and/or the discharge summary) 
D Tumour not entirelv. resected 
D Tumour entirelv resected 
D Unknown 
19. Operative findings, Distant (pis. obtain info. from the operative report &;or the discharge 
summary): 
No Metastatic Metastatic 
Disease Disease Found 
D D 
Positive 
D 
D 
D 
D 
Proximal 
Distal 
Radial 
Other 
Type of Metastatic Disease Found: 
o Ascites 
D Mesenteric nodes, other than in mesentery of planned 
resection 
o Liver 
o Lung 
D Omentum 
D Abdominal wall 
D Ovaries 
o Bone 
D Peritoneum 
o Mesentery 
D Other Please Specify: 
Unknown 
D 
Unknown 
D 
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(CONCURRENT) PRIMARY DIAGNOSIS # Please see Ques.#2 to identify Site #. 
(Please complete a separate form for each primary diagnosis). 
21. Grade of Prima : 
Well Moderately 
Differentiated Differentiated 
0 0 
22. Cell T 
Adenoca. 
o NOS 
0 
0 
0 
0 
23. Vascular Invasion: 
0 Yes 
0 No 
0 Unknown 
24 L h t" I _, mp1 a 1c nvas1on 
0 Yes 
0 No 
0 Unknown 
25. Perineural Invasion: 
0 Yes 
0 No 
0 Unknown 
Poorly 
Differentiated 
0 
Undifferentiated Unknown 
0 0 
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26. Patient Enrolled in a clinical trial: 
I ~ I ~~s Please Specify: 
o Unknown 
27. Oncologist(s): 0 Not assessed 
I!: I!: 
28. Chemotherapy given (If yes pis. oomplete Treatm ent table below & attach all flow sheets): 
Yes Type No (Pis. go to #32) Unknown 
0 o Adjuvant 0 0 
o Palliative 
Height Weight B.S.A . 
-
em . _kg 
--
m2 
o Unknown o Unknown o Unknown 
CHEMOTHERAPY TREATMENT (For cyclic chemo., pis. report each cycle separate/ye.g. 1, 2, 3, 
4) 
FOR BASELINE DIAGNOSIS 
First Course Only. Flow sheet attached Y /N: 
Cycle# Name Drug Dosage IV/PO Days Given Date Given Palliative 
Therapy 
Response 
o Progression 
o Stable 
--
o Minor 
o Partial 
o Complete 
o Unknown 
0 Progression 
o Stable 
--
0 Minor 
o Partial 
o Complete 
o Unknown 
o Progression 
o Stable 
--
o Minor 
o Partial 
o Complete 
0 Unknown 
o Progression 
o Stable 
--
o Minor 
o Partial 
o Complete 
0 Unknown 
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--
--
--
--
32. Radiation given :please attach all flow sheets whe re available) 
Yes Type No Unknown 
0 o Adjuvant 0 0 
o Palliative 
CLINICAL FOLLOW-UP SINCE BASELINE DIAGNOSIS 
33. New cancer event in the four ears followin the initial dia nosis: 
Yes Check off as many that apply and complete the corresponding 
section. 
o o Locoregional Recurrence 
D Distant Recurrence 
o Other Non-Colorectal Primary 
D Colorectal Primary 
D Death 
34. Patient Enrolled in a clinical trial since baseline: I ~ I ~~ Please Specify 
o Unknown 
o Progression 
o Stable 
o Minor 
o Partial 
o Complete 
0 Unknown 
o Progression 
o Stable 
o Minor 
o Partial 
o Complete 
o Unknown 
o Progression 
o Stable 
o Minor 
o Partial 
o Complete 
o Unknown 
o Progression 
o Stable 
o Minor 
o Partial 
o Complete 
o Unknown 
None Unknown 
0 0 
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FIRST LOCOREGIONAL RECURRENCE 
D None (go to #43) 
If applicable, please attach copies of documentation (i.e. radiology reports, clinic 
notes, pathology reports, operative reports, etc.) with the date of first detection of 
site(s) of first loco regional recurrence(s). 
35. Sites of involvement at time of first locor ional recurrence lease check off all that a f : 
First Diagnosed First Diagnosed First Diagnosed 
Site Da Month Year 
o Anastomosis 
o Mesente 
o Abdominal Wall (not incisional) 
o Incisional 
o Pelvis 
o Other Please specify: _____ _ 
o Unknown 
0 
0 
o Unknown 
37. Treatment for locoregional recurrence: 
0 Yes 
0 No 
0 Unknown 
38. Oncologist(s): 0 Not assessed 
I ~: I!: 
39. Chemotherapy given (If yes pis. complete Treatm ent table below & attach all flow sheets): 
Yes Type No (Pis. go to #A6) Unknown 
0 o Adjuvant 0 0 
o Palliative 
Height Weight B.S.A . 
-
em . _kg 
--
m2 
o Unknown o Unknown o Unknown 
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CHEMOTHERAPY TREATMENT (For cyclic chemo., pis. report each cycle separatelye.g. 1, 2, 3, 
4) 
FOR FIRST LOCOREGIONAL RECURRENCE 
First Course. Flow sheet attached Y/N: 
Cycle# Name Drug Dosage IV/PO Days Given Date Given Palliative 
Therapy 
Response 
o Progression 
o Stable 
--
o Minor 
o Partial 
o Complete 
o Unknown 
o Progression 
o Stable 
--
o Minor 
o Partial 
o Complete 
o Unknown 
o Progression 
o Stable 
--
0 Minor 
o Partial 
o Complete 
o Unknown 
o Progression 
o Stable 
o Minor 
--
o Partial 
o Complete 
o Unknown 
o Progression 
o Stable 
--
o Minor 
o Partial 
o Complete 
o Unknown 
o Progression 
o Stable 
o Minor 
--
o Partial 
o Complete 
o Unknown 
o Progression 
o Stable 
--
o Minor 
o Partial 
o Complete 
0 Unknown 
o Progression 
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o Stable 
--
o Minor 
o Partial 
o Complete 
o Unknown 
40. Radiation given please attach all flow sheets/ whe re available). 
Yes Type No Unknown 
0 o Adjuvant 0 0 
0 Palliative 
41. Other treatment given (please attach all documents): 
0 Yes 
0 No 
0 Unknown 
42. Other Locoregional recurrence sites after the first site was identified (please check off all that 
applv): 
Diagnosed Diagnosed Diagnosed 
Site Day Month Year 
0 Anastomosis 
0 Mesentery 
0 Abdominal Wall (not incisional) 
0 Incisional 
0 Pelvis 
0 Other Please specify: 
0 Unknown 
FIRST DISTANT RECURRENCE 
D None (go to #51) 
If applicable, please attach copies of documentation (i.e. radiology reports, clinic notes, pathology 
reports, operative reports, etc.) with the date of first detection of site(s) of first distant 
recurrence(s). 
43. Sites of involvement at time of first distant recurrence (please check off all that apoly): 
First Diagnosed First Diagnosed First Diagnosed 
Site Day Month Year 
0 Liver 
0 Lung 
0 Bone 
0 Ascites 
0 Non-mesenteric lymph nodes (except 
supraclavicular) Please specify: 
0 Supraclavicular nodes 
0 Brain 
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r------- ---------------------------------
o Skin, except incision 
Pleases i : 
o Other 
Please speci : 
44. Sur e for distant recurrence: 
o Yes Please speci 
o No 
o Unknown 
45. Treatment for distant recurrence: 
0 Yes 
0 No 
0 Unknown 
46. Oncologist(s): 0 Not assessed 
I~: I !: 
47. Chemotherapy given (If yes pis. complete Treatm ent table below & attach all flow sheets): 
Yes Type No (Pis. go to #86) Unknown 
0 o Adjuvant 0 0 
o Palliative 
Height Weight B.S.A . 
-
em . _ kg 
- ·-
m2 
o Unknown o Unknown o Unknown 
CHEMOTHERAPY TREATMENT (For cyclic chemo., pis. report each cycle separately e.g. 1, 2, 3, 
4) 
FOR FIRST DISTANT RECURRENCE 
First Course. Flow sheet attached Y /N: 
Cycle# Name Drug Dosage IV/PO Days Given Date Given Palliative 
Therapy 
Response 
o Progression 
o Stable 
o Minor 
--
o Partial 
o Complete 
o Unknown 
o Progression 
o Stable 
--
o Minor 
o Partial 
o Complete 
o Unknown 
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D Progression 
o Stable 
--
D Minor 
D Partial 
D Complete 
D Unknown 
D Progression 
D Stable 
--
D Minor 
D Partial 
D Complete 
D Unknown 
D Progression 
D Stable 
--
D Minor 
D Partial 
D Complete 
D Unknown 
D Progression 
o Stable 
--
D Minor 
D Partial 
D Complete 
D Unknown 
D Progression 
o Stable 
--
D Minor 
D Partial 
D Complete 
D Unknown 
D Progression 
o Stable 
--
D Minor 
D Partial 
D Complete 
D Unknown 
48. Radiation given :please attEch all flow sheets, whe re available) 
Yes Type No Unknown 
D D Adjuvant D D 
D Palliative 
49. Other treatment given (please attach all documents}. 
D Yes 
D No 
D Unknown 
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50. Other Distant recurrence sites after the first site was identified ( ojease check off all that apply): 
Diagnosed Diagnosed Diagnosed 
Site Day Month Year 
0 Uver 
0 Lung 
0 Bone 
0 Ascites 
0 Non-mesenteric lymph nodes (except 
supraclavicular) Please specify: 
0 Supraclavicular nodes 
0 Brain 
0 Skin, except incision 
Please specify: 
0 Adrenal gland 
0 Other 
Please specify: 
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OTHER NON-COLORECTAL PRIMARYCSl 
0 None (go to #55) 
51. Hospital of Diagnosis: I Name I City or Town I MOH Code 
52. Sites of new Non-Colorectal Prima since the initial dia nosis of Colorectal cancer: 
Cancer Site 4-Di it ICD-9 Code 
1. 
2. 
3. 
4. 
5. 
53. Date(s) of diagnosis of new Non-Colorectal Primary Cancer(s) (please use histological date) : 
Cancer Da Month Year 
1. 
2. 
3. 
4. 
5. 
54. Stage(s) of new Non-Colorectal Primary Cancer(s): 
Cancer Stage 0 Stage 1 Stag_e 2 Stage 3 Stage 4 Unknown 
1. 0 0 0 0 0 0 
2. 0 0 0 0 0 0 
3. 0 0 0 0 0 0 
4. 0 0 0 0 0 0 
5. 0 0 0 0 0 0 
NEW COLORECTAL PRIMARYCSl 
0 None (go to #80) 
55. Site of Cancer(s): 
Cancer Site Name 4-Digit Diag. Diag. Diag. Unknown 
ICD-9 Code Day Month Year 
1. 0 
2. 0 
3. 0 
4. 0 
5. 0 
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lease check all that a 
0 
0 Consti ation 
0 Diarrhea 
0 Pain 
0 Wei ht Loss 
0 Other Please Specify: 
0 Unknown 
57. Method of colorectal cancer dia check all that a pi 
0 
0 
0 
0 
0 Barium enema 
0 Chest x-ra 
0 Chest CT scan 
0 Abdominal CT scan 
0 Ultrasound 
0 Other PleaseS 
0 Unknown 
58. Type of definitive surgery for colorectal cancer (SEER coding used) (please attach all pathology 
and operative reports for this colorectal cancer): 
0 None (please go to #18) 
0 Local tumour destruction, i.e. laser, electrocautery 
0 Local surgical exdsion with spedmen i.e. polypectomy, snare 
0 Segmental resection, not hemi-colectomy i.e. cecectomy, appendectomy, sigmoidectomy, partial 
resection of transverse colon and flexures, iliocolectomy, enterocolectomy, partial colectomy, NOS 
o Low Anterior 
0 Hemi-colectomy, but not total. Right or left, must include a portion of transverse colon 
0 Abdominoperineal resection 
0 Total or subtotal colectomy, not rectum 
0 Colectomy NOS 
0 Segmental colectomy + other organs (*Please specify below) 
0 Hemi-colectomy + other organs (*Please specify below) 
0 Total or subtotal colectomy or+ other organs (*Please specify below) 
0 Abdominoperineal resection+ other organs (*Please specify below) 
0 Other Please Specify: 
0 Unknown 
*If Other Organs were removed: 
o S leen 
o Gallbladder 
0 
o Pancreas 
o Small intestine 
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0 Liver 
0 Abdominal wall, Retroperitoneum 
0 Adrenal 
0 Kidney 
0 Bladder 
0 Urethra 
0 Ovary 
0 Uterus 
0 Vagina 
0 Prostate 
0 Other Please Specify: 
0 Unknown 
59 If d no surgery was pe orme ., reason: 
0 Patient Refusal 
0 Antecedent Death 
0 Medical Contraindication 
0 Other Please Specify: 
0 Unknown 
Unknown 
6 P h I · I S age of disease (from all information available): 2. at oog1ca t 
T 
N 
M 
0 Unknown 
f d" 63 St 1sease age o at initial diagnosis (from all information available) 
0 Stage 0 
0 Stage 1 
0 Stage 2 
0 Stage 3 
0 Stage 4 
0 Unknown 
hi d tid 64. Other Pat o ogy I enti 1e 
Yes Type: No Unknown 
0 o Crohn's Disease 0 0 
o Ulcerative colitis 
o Diverticulosis/it is 
o Perforation 
o Other Please Spedfy: 
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65. Preoperative CEA (carcinoembryonic antig en): 
0 Yes ug/L 
0 No 
0 Unknown 
66. Date of Blood Test for Preoperative CEA: 
DD 
MM 
yyyy 
0 Unknown 
67 D f ate o surgery: 
DD 
MM 
yyyy 
0 Unknown 
68. Primary surgery hospital: I Name I City or Town I MOH Code 
69. Operating Surgeon: 
70. Operative findings, local (residual tumour) (please obtain information from the operative report 
and/or the discharge summary) 
0 Tumour not entirelv resected 
0 Tumour entirelv resected 
0 Unknown 
71. Operative findings, Distant (pis. obtain info. from the operative report &jor the discharge 
summary): 
No Metastatic Metastatic Type of Metastatic Disease Found: Unknown 
Disease Disease Found 
0 0 o Ascites 0 
o Mesenteric nodes, other than in mesentery of planned 
resection 
o Liver 
o Lung 
o Omentum 
o Abdominal wall 
o Ovaries 
o Bone 
o Peritoneum 
o Mesentery 
o Other Please Specify: 
72. Margins: 
Negative Positive Unknown 
0 0 Proximal 0 
0 Distal 
0 Radial 
0 Other Please Specify: 
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(CONCURRENT) PRIMARY DIAGNOSIS# Please see Ques.#S to identify Site#. 
(Please complete a separate form for each primary diagnosis). 
73. Grade of Primary: 
Well Moderately 
Differentiated Differentiated 
0 0 
74. Cell Type: 
Adenoca. 
0 NOS 
o Mucinous 
o Signet ring cell 
o Other Please specify: 
o Unknown 
75. Vascular Invasion: 
o Yes 
o No 
o Unknown 
76. L-ymphatic Invasion: 
o Yes 
o No 
0 Unknown 
77. Perineural Invasion: 
o Yes 
o No 
0 Unknown 
Poorly 
Differentiated 
0 
Undifferentiated Unknown 
0 D 
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78. Oncologist(s): D Not assessed 
I ~: I!: 
79. Chemotherapy given (If yes, pis. complete Treatme nt table below & attach all flow sheets): 
Yes Type No (Pis. go to #D28) Unknown 
D D Adjuvant D D 
D Palliative 
Height Weight B.S.A . 
-
em . _ kg 
--
m2 
D Unknown o Unknown D Unknown 
CHEMOTHERAPY TREATMENT (For cyclic chemo., pis. report each cycle separate/ye.g. 1, 2, 3, 
4) 
FOR NEW CRC PRIMARY 
First Course Flow sheet attached Y /N: 
-
Cycle# Name Drug Dosage IV/PO Days Given Date Given Palliative 
Therapy 
Response 
D Progression 
o Stable 
--
D Minor 
D Partial 
o Complete 
D Unknown 
D Progression 
o Stable 
--
D Minor 
D Partial 
D Complete 
o Unknown 
D Progression 
o Stable 
--
o Minor 
D Partial 
D Complete 
o Unknown 
D Progression 
o Stable 
--
o Minor 
o Partial 
D Complete 
D Unknown 
o Progression 
o Stable 
--
o Minor 
o Partial 
D Complete 
o Unknown 
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o Progression 
o Stable 
--
o Minor 
o Partial 
o Complete 
o Unknown 
o Progression 
o Stable 
--
0 Minor 
o Partial 
o Complete 
0 Unknown 
o Progression 
o Stable 
--
0 Minor 
o Partial 
o Complete 
o Unknown 
79. Radiation given 'jJiease atliJch all flow sheets whe re available) 
Yes Type No Unknown 
0 o Adjuvant 0 0 
o Palliative 
DEATH 
80. Date of Death: 
I~ I 
81. Cause of Death lease attach ca of death certificate if available : 
o Colorectal cancer 
o Unknown 
8 2. Autopsy per orm f ed (please attach copy of report if available): 
0 Yes 
0 No 
0 Unknown 
83. Location of Death: 
o Hospital Please spedfy: 
o Home 
o Hospice 
o other 
o Unknown 
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DATE OF FINAL CHART NOTE: 
PATIENT HAS BEEN REFERRED TO THE CARE OF: DR. 
ADDITIONAL FOLLOW-UP REQUIRED (YIN): 
....--
Date form Completed: 
--
(dd/mmmjyyyy) 
Abstractor's Initials: 
--
-
-----
ADDffiONAL NOTES: 
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